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SUMMARY  
This final report summarizes the results of two reviews and a scoping study related to Canine leishmaniosis 
(CanL). Three objectives were addressed in this project. Objective 1 was to summarize relative sensitivity and 
specificity estimates of assays used to detect infection in dogs with Leishmania infantum in studies of naïve dogs 
in areas where Leishmania infantum infection is endemic. Objective 2 was to summarize data available to 
estimate the prevalence of parasitological cure (failure to detect organism) after a 12-month follow-up period in 
animals treated with meglumine antimoniate, miltefosine, and allopurinol or combinations of these drugs for 
canine leishmaniosis. Objective 3 was to assess diagnostic test characteristics of PCR assays and serological 
assays (ELISA or IFAT) from studies that use experimental models of Canine leishmaniosis. The same 
comprehensive search was used for all objectives. The searches yielded 7,405 records. After duplicates were 
removed, 3,865 records remained. Of these, 243 were broadly identified as diagnostic test evaluation studies and 
at the 2
nd
 level of screening 18 were considered longitudinal studies. The 18 references were then assessed based 
on the full text and 7 were considered relevant to the review. The assays assessed by these studies were PCR on 
skin, buffy coat, bone marrow, blood and conjunctiva, and IFAT and ELISA. For objective 2, 40 potentially 
relevant records were identified as treatment comparison studies. After full-text screening, 13 studies were 
included in the review. The treatments varied greatly, and few comparative efficacy estimates were provided. No 
treatment was associated with 100% cure after 180 days follow-up. For objective 3, 513 citations were identified 
and the full texts of 169 articles were obtained. Sixty-two articles described at least one of the assays requested 
(PCR, ELISA or IFAT) and 18 articles described the use of a PCR and either ELISA and/or IFAT.  
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INTRODUCTION AND OBJECTIVES 168 
1. General background and rationale  169 
Regulation (EC) No 998/2013 of the European Parliament and of the Council on the animal health 170 
requirements applicable to the non-commercial movement of pet animals and amending Council 171 
Directive 92/65/EEC1 ('the Regulation'), provides that the Commission may adopt species-specific 172 
preventive health measures for the control of diseases or infections other than rabies likely to spread 173 
due to the movement of pet animals, where they are necessary for the protection of public health or the 174 
health of pet animals. Those measures shall be scientifically justified and proportionate to the risk of 175 
spreading those diseases due to such movement.  176 
Canine leishmaniosis (CanL) caused by infection with Leishmania infantum is a major global vector-177 
borne zoonotic disease and is potentially fatal to humans and dogs. The latter are the most important 178 
natural reservoir and should therefore be the main target of control measures. Leishmaniosis is known 179 
to be endemic in more than 70 countries in the world, including certain regions of southern Europe. 180 
The movement of infected dogs from endemic regions, together with the potential expansion of sand 181 
fly vector populations in Europe, might represent a risk of introducing the disease into non-endemic 182 
countries. For that reason, canine leishmaniosis might fall under the category of diseases other than 183 
rabies that require preventive health measures to be adopted by means of a Commission delegated to 184 
act in accordance with the Regulation, in order to ensure protection of those Member States in which  185 
endemic infection with Leishmania infantum has not been recorded. 186 
To support the Commission in the possible preparation of such an act, the Commission requested 187 
EFSA to assess the available scientific information regarding canine leishmaniosis and to evaluate the 188 
relevance of measures aimed at mitigating the risk of introducing the disease through the movement of 189 
dogs. Testing dogs that move from endemic areas into disease-free areas for Leishmania infantum 190 
infections and treating positive dogs could be possible measures of reducing the risk of introduction 191 
into free areas in the EU. 192 
2. Objectives  193 
This contract had three objectives, and within each objective, several sub-objectives. 194 
2.1. Objective 1 -Sensitivity and specificity of diagnostic assays in naïve dog populations 195 
Objective 1 was to summarize relative sensitivity and specificity estimates of assays used to 196 
detect infection in dogs with Leishmania infantum reported in studies of naïve dogs in areas 197 
where Leishmania infantum infection is endemic.   198 
2.2. Objective 2 -Prevalence of parasitological cure after treatment 199 
Objective 2 was to summarize data available to answer the question “What is the prevalence of 200 
parasitological cure (failure to detect organism) after 12 months follow-up period in animals 201 
treated with meglumine antimoniate, miltefosine, and allopurinol or combinations of these 202 
drugs for canine leishmaniosis?”  203 
2.3. Objective 3-Identifying challenge studies that might report diagnostic test 204 
characteristics (PCR, ELISA, IFAT) 205 
Objective 3 was to conduct an extensive search and study selection process to identify studies 206 
relevant to the review designed to “Assess diagnostic test characteristics of PCR assays and 207 
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serological assays (ELISA or IFAT) from studies that use experimental models of Canine 208 
leishmaniosis.”  209 
MATERIALS AND METHODS 210 
3. Protocol and registration 211 
The protocols for the three objectives were developed with EFSA staff and the EFSA working group. 212 
The process of protocol development is documented in a report delivered to EFSA on the 10
th
 of 213 
October 2014. The protocols for each objective are included in Appendix A. , Appendix B. and 214 
Appendix C.  The protocol for the diagnostic test evaluation review was developed using the approach 215 
and subheadings recommended in the RevMan software (RevMan, 2012). The protocol for the 216 
treatment review was developed using the approach recommended by EFSA (EFSA, 2010) and, 217 
although a reporting guideline, the protocol was framed using the PRISMA guidelines for 218 
interventions (Liberati et al., 2009).  219 
4. Eligibility criteria 220 
4.1. Objective 1- Sensitivity and specificity of diagnostic assays in naïve dog populations 221 
For Objective 1, the review about the sensitivity and specificity of diagnostic tests in naïve dogs, the 222 
eligibility criteria were:  223 
4.1.1. Types of studies 224 
Studies that enrolled dogs that were naïve for Leishmania infantum infection and lived or were 225 
introduced to an endemic region were eligible for the review. The studies had to follow the dog over 226 
time to detect changes in Leishmania infantum infection status  227 
4.1.2. Participants  228 
The target population of interest were naïve dogs at risk of Leishmania infantum in Europe introduced 229 
into or living in endemic regions. Naïve dogs were defined as dogs that tested negative for Leishmania 230 
infantum using both PCR (using any sample) and serology based on ELISA or IFAT.   231 
4.1.3. Index and comparator tests  232 
The aim was to extract sensitivity and specificity data from these studies. The authors may have tested 233 
the animals with a PCR or serology test of choice during the study and determined the apparent 234 
prevalence of infection. Then the authors may have compared the results of the PCR of choice to other 235 
PCR assays, the same PCR assay on a different tissue, or the serological assays ELISA or IFAT. 236 
Therefore, the gold standard was the author(s)’ “preferred” PCR and this varied between studies. The 237 
comparator test was that reported by the authors, provided it was either a PCR test/tissue or ELISA or 238 
IFAT.  239 
4.1.4. Target conditions  240 
The target condition of interest was infection with leishmaniosis caused by infection with Leishmania 241 
infantum based on the author(s)’ preferred PCR assay and test sample.   242 
4.2. Objective 2- Prevalence of parasitological cure after treatment  243 
For the 2
nd
 review, about the treatment options for canine infection with Leishmania infantum, the 244 
eligibly criteria were: 245 
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4.2.1. Type of study 246 
Relevant studies were controlled trials that randomly allocated animals to treatment groups.  247 
4.2.2. Participants 248 
The relevant study population was defined as dogs with confirmed cases of canine leishmaniosis in the 249 
European region. The European region is defined as member countries of the OIE European region 250 
(http://www.oie.int/fileadmin/Home/eng/About_us/docs/pdf/2009_Commission_Europe_A.pdf), and 251 
included northern Asia (e.g., Russia, Ukraine, Uzbekistan), Turkey, Israel, and several other non-EU 252 
countries.  253 
4.2.3. Intervention 254 
 The relevant population was treated with any regime that contained meglumine antimoniate, 255 
miltefosine and allopurinol.  256 
4.2.4. Outcome measures 257 
Primary outcome: The primary outcome of interest was a prevalence of parasitological cure at greater 258 
than 12 months after the initiation of therapy. This was defined as absence of parasites, assessed using 259 
an accurate PCR (based on other review) or xenodiagnosis after confirmation of the presence of the 260 
parasites prior to or early in the treatment protocol.   261 
4.3. Objective 3--Identifying challenge studies that might report diagnostic test 262 
characteristics (PCR, ELISA, IFAT) 263 
The objective of this task was to identify challenge studies of dogs infected with Leishmania infantum 264 
that reported using PCR, IFAT, or ELISA. The aim was to identify such studies, and provide the list of 265 
such studies to EFSA. We did not assess if the data needed to determine sensitivity and specificity 266 
were explicitly reported.   267 
5. Information sources  268 
A range of information sources indexing published research were searched for studies reporting on 269 
canine leishmaniosis (Table 1). Information on on-going or recently completed trials, unpublished 270 
research, and research reported in the grey literature was identified by searching databases that index 271 
conference proceedings and specialised search engines: Conference Proceedings Citation Index – 272 
Science and Open Grey. Where possible, search results were downloaded from the information 273 
sources and imported into EndNote® bibliographic management software.  De-duplication was 274 
undertaken using a number of algorithms including those in EndNote ® and DistillerSR ® (Ottawa, 275 
ON, Canada). 276 
6. Search  277 
The search strategy used to identify studies for all three objectives was the same. The area of 278 
differentiation was the process of selecting studies, which is described in study selection (Section 7) 279 
below. The search strategy used to identify studies indexed in the Science Citation Index (Web of 280 
Knowledge; Thompson Reuters) is presented in Figure 1.  The strategy comprised three key elements: 281 
 The population: dogs (search line 1) 282 
 The exposure: Leishmania infantum (search line 2) 283 
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 The setting: The 53 countries that make up the OIE World Organisation for Animal Health 284 
Regional Commission for Europe (search lines 4 to 5).   285 
Restricting a search by geographic setting is difficult to achieve sensitively due to the poor reporting of 286 
a study’s location in the title, abstract, or other fields of database records.  The strategy took the 287 
approach of excluding records with a non-eligible country in the address field but not a country 288 
belonging to the OIE Regional Commission for Europe.  Constructing the strategy in this way ensured 289 
that records that contained a European, and a non-European country in the address field were not 290 
excluded incorrectly.  Although this approach has the potential to miss relevant studies, for example 291 
those that took place in a European country but were conducted by an author from the United States, it 292 
was necessary to limit by setting in order to increase precision (by removing non-relevant studies from 293 
the Americas, Australasia, and Africa) and, therefore, ensure that the volume of records retrieved was 294 
manageable within the resource constraints of the project. 295 
Increasing precision by introducing treatment and diagnoses as additional key elements was not 296 
feasible as scoping searches indicated the wide range of keywords needed to capture these elements 297 
satisfactorily, many of them non-specific, meant that the number of records retrieved was not 298 
significantly reduced.  The searches were not limited by date, language, or study design.  299 
The search strategy developed for the Science Citation Index was adapted appropriately to perform 300 
efficiently in other information sources.  Adaptation included a consideration of database interface 301 
differences (search syntax) as well as adaptation to different indexing languages. The strategies used to 302 
search each information source are presented in Appendix D.  303 
7. Study selection  304 
The study selection process differed slightly for each objective therefore these are described 305 
separately.    The screening questions were developed in DistillerSR®.  306 
7.1. 1st level screening for Objective 1 (Sensitivity and specificity of diagnostic assays in 307 
naïve dog populations) and Objective 2 (Prevalence of parasitological cure after 308 
treatment).   309 
The purpose of this step was to identify the body of work likely to be relevant to the topics of interest.  310 
Only one level of screening was used to identify references of potential relevance within the available 311 
literature. The following questions were used to screen references: 312 
Question 1: Does the title or abstract describe a primary study in which data may have been collected 313 
from which diagnostic test characteristics could be calculated for one or more of the following assays 314 
of interest for canine leishmaniosis: PCR, IFAT, or ELISA? Include only studies evaluating tests in 315 
dogs (i.e., exclude sand flies, humans, etc.) and exclude studies obviously evaluating L. Mexicana, or 316 
L. brasiliensis.  317 
 Yes—data on assay of interest  318 
 Diagnostic test evaluation (DTE) but assay type not discernible  319 
 No  320 
Question 2: Does the title or abstract describe a primary study comparing treatments or treatment 321 
regimens in dogs with naturally occurring or induced canine leishmaniosis, in which at least one of 322 
the treatments was one of the following: Meglumine antimoniate (Glucantime), Miltefosine 323 
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(hexadecyl-phosphocholine), or Allopurinol? Exclude studies obviously evaluating, L. Mexicana, 324 
or L. brasiliensis  325 
 Yes—treatment of interest included  326 
 Treatment comparison but treatment type is not discernible  327 
 No  328 
Question 3: Was the study conducted in a European country based on the OIE definition of a 329 
European country? 330 
 Yes (include for data characterization) 331 
 Not discernible (include for data characterization) 332 
 No (reference is excluded) 333 
7.1.1. 2nd level selection steps for Objective 1 (Sensitivity and specificity of diagnostic assays in 334 
naïve dog populations) 335 
Studies that responded yes to either of the 1
st
 two items in question 1 of the initial screening were then 336 
assessed further to determine if they might be eligible and the assays used. The 2nd level of screening 337 
asked:  338 
Does the study describe longitudinal studies in which Leishmania-naïve dogs or introduced dogs into 339 
an endemic area were followed with PCR (kDNA and/or rRNA) AND serology? 340 
 Yes-proceed to next level 341 
 No - exclude 342 
For the final level of screening, based on the full text, the following question was used:  343 
Did the study use a testing protocol to assess naïve dogs that included both PCR and serology (ELISA 344 
or IFAT)? 345 
 Yes-proceed to data extraction 346 
 No - exclude 347 
These series of questions were tested on a test set of abstracts and modified as necessary. When 348 
agreement between the two independent reviewers was high (kappa > 90%) screening of all abstracts 349 
took place. Conflicts were resolved by discussion.  350 
7.1.2. 2nd level selection steps for Objective 2 (Prevalence of parasitological cure after 351 
treatment)  352 
Studies for which reviewers responded yes to either of the 1
st
 two items in question 1 of the initial 353 
screening were then assessed further to determine if they might be eligible and the assays used. Note 354 
that these questions do represent a deviation from the protocol. The protocol called for inclusion of 355 
only randomized studies and studies with 12-month follow-up. As there were so few such studies that 356 
met these criteria, the review team modified these criteria to expand the list of included studies. The 357 
subsequent screening conducted on the abstract and titles included the following questions:  358 
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Does the study describe a controlled trial that assesses the treatment of canine leishmaniasis with one 359 
of the drugs of interest (Meglumine antimoniate, Miltefosine, Allopurinol) either alone or in 360 
combination with another drug of interest?  361 
1. Yes 362 
2. No   363 
Was the presence of parasites confirmed prior to beginning treatment or early in the treatment 364 
protocol? 365 
1. Yes, by PCR or xenodiagnosis  366 
2. Yes, by microscopy/culture  367 
3. Yes, by other testing method  368 
4. No  369 
Was the presence of parasites evaluated at least 6 months after the initiation of therapy? 370 
1. Yes, with PCR or xenodiagnosis, 12 months or more 371 
2. Yes, with PCR or xenodiagnosis, 6-11 months 372 
3. Yes, by microscopy or culture 373 
4. Yes, by other testing method 374 
5. No/Not discernible 375 
7.1.3. Selection steps for Objective 3 (Identifying challenge studies that might report 376 
diagnostic test characteristics (PCR, ELISA, IFAT))  377 
For the third objective the approach was to use the full search provided by the York team and use 378 
Endnote ® to identify studies that used the term “challenge /induced/ experiment” in the title or 379 
abstract from the full search. For this group of studies, the review team then tried to obtain the full text 380 
for as many studies as could be found and that were in English. The review team then read the full text 381 
of these studies to determine if the authors reported using both PCR (any PCR on any tissue) and any 382 
ELISA or IFAT assay. The screening conducted on the full text included the following question: 383 
1. Does the study include data, which may be used to calculate the diagnostic test characteristics of 384 
the following assays of interest for canine leishmaniosis: PCR, IFAT, or ELISA? Include studies 385 
with data in figures, tables or text. Note the data may be reported as apparent prevalence or 386 
prevalence and is unlikely to be reported as sensitivity and specificity.  387 
Yes- provide this reference to EFSA for data extraction 388 
No (exclude) 389 
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8. Data collection process  390 
For Objective 1 (Sensitivity and specificity of diagnostic assays in naïve dog populations) and 391 
Objective 2 (Prevalence of parasitological cure after treatment), the study selection process was 392 
conducted by 2 independent reviewers. After initially doing a small subset of studies to ensure 393 
agreement and similar understanding of the eligibility criteria, screening proceeded until all citations 394 
were completed.  Conflicts were resolved by discussion. For the data extraction, which is relevant for 395 
Objective 1 and Objective 2 only, a similar process was used and conflicts resolved by discussion. For 396 
Objective 1 data extraction was conducted directly into a MS word ® document, as it was not possible 397 
to design a useful form in Distiller SR®. For Objective 2, data extraction was conducing using forms 398 
in Distiller SR®.   399 
9. Data items  400 
Information was extracted about the study characteristics associated with establishing external 401 
validity:  country, year, species etc. For Objective 1 (Sensitivity and specificity of diagnostic assays in 402 
naïve dog populations) and Objective 2 (Prevalence of parasitological cure after treatment), the 403 
relevant outcome data were extracted and the risk of bias assessed. The proposed data collection forms 404 
are listed in Appendix A. Appendix B. and Appendix C.  405 
10. Risk of bias in individual studies 406 
The risk of bias tool used for Objective 1 is included in Appendix E. The bias assessment tool for 407 
Objective 2 is included in Appendix F. The 3
rd
 Objective did not include risk of bias assessment in its 408 
scope.  409 
11. Summary effect size  410 
For Objective 1 (Sensitivity and specificity of diagnostic assays in naïve dog populations) it was 411 
considered possible but not probable that some studies would use the same reference and index test, 412 
and if so, a summary sensitivity and specificity would be calculated. For Objective 2 (Prevalence of 413 
parasitological cure after treatment), as no pairwise comparison of treatment options was of interest, it 414 
was anticipated from the outset that no effect size would be calculated. Objective 2 (Prevalence of 415 
parasitological cure after treatment) did aim to extract the prevalence of cure from each relevant 416 
treatment arm of interest but as these have different baselines it is not valid to combine into a summary 417 
measure. It would only be valid to extract comparative measures of cure relative to another treatment 418 
option.  419 
12. Synthesis of results  420 
The proposed approach to presentation was to present study-level characteristics, study-level outcomes 421 
and study-level risk of bias. We did not contact authors to obtain missing data for any objectives. This 422 
is a potential limitation of the review. Recently, we conducted a review and around 30% of original 423 
papers did not report measures of variation and by contacting the authors, we were able to obtain 424 
information on numerous papers.  However, this was a long process (months). Imputation methods for 425 
studies that did not report measures of variation for the outcomes of interest were not used. 426 
The approach to evidence synthesis depended upon the frequency of the outcomes of interest within 427 
the relevant studies. Tables that described the outcomes used and the associations observed are 428 
reported. We attempted to prepare forest plots for sensitivity and prevalence data when feasible.  429 
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13. Risk of bias across studies   430 
Given the absence of a specific effect size of interest, we did not anticipate we would be able to assess 431 
small study effects for either Objective 1 or Objective 2.  432 
14. Additional analyses   433 
No additional analyses were proposed or conducted.  434 
RESULTS 435 
From this point forward in the report, the PRISMA items related to each objective are grouped 436 
together.  437 
15. Study selection for Objective 1: Sensitivity and specificity of diagnostic assays in naïve 438 
dog populations 439 
The searches yielded 7,405 records.  The source of these records is presented in Table 2.  The flow 440 
chart of studies is reported in Figure 2.  After duplicates were removed, 3,865 records remained. Of 441 
the 3,865 references screened, 243 were broadly identified as diagnostic test evaluation studies and at 442 
the 2
nd
 level of screening 18 were considered longitudinal studies. The 18 references were then 443 
assessed based on the full text and 7 were considered relevant to the review. The citations and 444 
rationale for exclusion are included in Table 2.  445 
16. Study characteristics for Objective 1 -Sensitivity and specificity of diagnostic assays in 446 
naïve dog populations 447 
The characteristics of the study populations are presented in Table 3 and Table 4. Table 3 contains 448 
information about the study population while Table 4 contains information about the assays used.   449 
17. Risk of bias within studies for Objective 1 -Sensitivity and specificity of diagnostic 450 
assays in naïve dog populations 451 
The risk of bias tables for these studies is presented in Table 5. The risk domains and interpretation of 452 
these are explained in Appendix E. Generally it was surprising that so few studies reported blinding of 453 
the animal’s status to the person running the test. Although tests like PCR are sometimes considered 454 
objective, knowledge of the status of the animal may affect the ability to “rerun” an assay or the 455 
interpretation of the assays if intermediate results are obtained. There is also concern about spectrum 456 
bias with respect to specificity, which would lead to overestimation of specificity, as the populations 457 
used to estimate specificity are likely not exposed to common causes of false positives. 458 
18. Results of individual studies for Objective 1 -Sensitivity and specificity of diagnostic 459 
assays in naïve dog populations 460 
The individual results reported by the authors for the assays assessed are included in Table 6. 461 
Synthesis of results for Objective 1. As very few studies used either the same assay or the same sample 462 
as the referent, it was not possible to combine the results of the study into a single summary number, 463 
such as a summary sensitivity or specificity. Most estimates of sensitivity of a serological assay 464 
compared to using the PCR as a gold standard were < 50%. In Table 6, there are 13 estimates of 465 
sensitivity that compare a PCR to serology (IFAT or ELISA) and of those only 4 have point estimates 466 
for estimates that are equal to or greater than 50%, so the majority of sensitivity estimates (9/13) are 467 
less than 50%. The PCR on the conjunctiva was not very sensitive based on the results reported by 468 
(Gramiccia et al., 2010) and (Otranto et al., 2013).  Gramiccia et al. (2010) reported that the sensitivity 469 
of PCR using conjunctiva swabs was 0% each time it was compared to PCR buffy coat over 3 testing 470 
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periods within 12 months of the start of the study. Gramiccia et al. (2010)  also reported that for the 3 471 
animals found positive based on buffy coat PCR after 1 year, the PCR of conjunctiva swabs was 100% 472 
sensitive. Another study that assessed conjunctiva swabs reported the sensitivity of 36% when the 473 
referent was PCR positive using the skin (4 detected using PCR on conjunctiva compared to 11 474 
detected PCR based on skin) (Otranto et al., 2013).  For the same period of time elapsed (~ 12 months) 475 
since enrolment, the relative sensitivity of the comparison for PCR based on bone marrow (54.5%) or 476 
IFAT (73%) compared to PCR based on skin samples were higher than the conjunctiva PCR versus 477 
skin PCR comparison. However Otranto et al. (2013) did not test if these comparative estimates were 478 
statistically significantly different i.e., Otranto et al. (2013) did not assess if the estimate of 54.5% 479 
sensitivity based on bone marrow PCR was statistically different from the estimate of 36%. Given the 480 
small samples sizes it is possible that the extent of random error might mean these estimates do not 481 
differ.  PCR based on skin was the most commonly used gold standard. There was no comparative 482 
assessment of PCR on bone marrow which was used by Olivia et al. (2006).  When PCR skin assays 483 
were compared to serological based tests, estimates of sensitivity ranged from 13% to 100% 484 
depending upon the study (Otranto et al., 2009; Otranto et al., 2013). Specificity had a much narrower 485 
range from 87% to 100% (Otranto et al., 2009; Otranto et al., 2010; Otranto et al., 2013).  486 
19. Risk of bias across studies for Objective 1- Sensitivity and specificity of diagnostic 487 
assays in naïve dog populations 488 
It was not possible to quantitatively assess the risk of bias across the studies.  489 
20. Additional analyses for Objective 1- Sensitivity and specificity of diagnostic assays in 490 
naïve dog populations 491 
No additional analyses were conducted. 492 
21. Study selection for Objective 2 -Prevalence of parasitological cure after treatment  493 
The flow chart is presented in Figure 3.  The source of these records is presented in Table 2.  After 494 
duplicates were removed, 3,865 records remained. Of these 3,865 references screened, 40 were 495 
identified as treatment comparison studies. The flow chart of studies is reported in Figure 3. During 2
nd
 496 
level full-text screening, it was discovered that few studies used a 360-day follow-up period; thus, the 497 
follow-up period criteria for inclusion was reduced to 180 days. Note that this is a deviation from the 498 
original protocol but was done to increase the amount of evidence available. After full-text screening, 499 
13 studies were included in the review; the excluded studies either did not report a treatment of interest 500 
or had a follow-up period less than 180 days. 501 
22. Study characteristics for Objective 2-Prevalence of parasitological cure after treatment 502 
Following full-text screening, 13 references were available for data extraction (Table 7). The 503 
manuscripts originated from 6 European countries: Italy (4 studies), Spain (2 studies), 504 
France/Italy/Spain (1 multicentre study), Germany (2 studies), France, Greece (2 studies), and the 505 
Netherlands (1 study). There was heterogeneity between the studies in each outcome category due to 506 
differing initial health statuses of dogs, treatments, treatment protocols, follow-up periods, tissue types 507 
sampled at follow-up, test type at follow-up (e.g., PCR or cytology to measure parasite load), and 508 
metrics of results reported (e.g., there is no standard metric to report parasite load).  509 
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23. Risk of bias within studies for Objective 2 -Prevalence of parasitological cure after 510 
treatment 511 
All studies included in this scoping review had a high risk of bias in their results (Tables 8, 9, 10, and 512 
11). As a result, caution should be taken in making inferences regarding treatment efficacy from these 513 
studies. 514 
24. Results of individual studies for Objective 2 -Prevalence of parasitological cure after 515 
treatment 516 
To improve readability of the findings, the included studies have been categorized by the type of test 517 
used at follow-up (outcome). The data from studies reporting PCR outcomes are reported in Table 12 518 
and Figure 4, xenodiagnosis outcomes are reported in Table 13, and parasite load quantification 519 
outcomes are reported in Table 14.  Using PCR as the detection method, the highest “cure risk” of 520 
33% was observed in dogs that received Meglumine antimoniate: 100 mg/kg SQ BID x 30 days with 521 
Allopurinol: 10 mg/kg PO BID x 365 days (Ariti et al., 2013). In that group, 5 of 15 dogs were PCR 522 
negative on blood, conjunctiva and lymph node after 720 days. However, this group contained dogs on 523 
the treatment for a variable period (some dogs constantly for 720 days while others for 360) and the 524 
authors did not differentiate the results by different treatment protocols. Therefore this cure risk is very 525 
hard to relate back to the drug protocol because in reality the group contains two protocols.  One study 526 
that reported the cure risks in the upper range (>90%) used xenodiagnoses for confirmation (Miro et 527 
al., 2011). This study used three protocols and the cure risks were 12/12, 8/9 and 5 /5 after 180 days 528 
(see Table 13 for protocols). Two aspects should be noted when interpreting this finding, 1
st
 this study 529 
used a shorter follow-up period than others (180 days compared to up to 720 days), and the result 530 
might be confounded by the assay. The validity of this result is dependent upon the validity of 531 
xenodiagnosis as an approach for the detection of chronic Leishmania infection, if a test has low 532 
sensitivity then many positive dogs will appear negative. The same can also be said for the study by 533 
Neogy et al. (1994), using bone marrow aspirates; this study reported a high cure risk after 180 days. It 534 
is unclear if the study had been longer, if this finding would have been reaffirmed, and the sensitivity 535 
of direct examination of bone marrow is unclear.  536 
Data was not extracted from four of the 13 included studies because reporting was incomplete (Table 537 
15). These studies were either (1) longitudinal case series, in which dogs may have initially been 538 
assigned to a treatment group, but the treatment protocol and/or follow-up time changed throughout 539 
the study or (2) did not report useable follow-up data at the dog- or treatment-group level (i.e., data 540 
were missing and unexplained). In the longitudinal case series studies, treatment protocols and follow-541 
up periods were often highly variable within groups as individual dog treatment and follow-up varied 542 
with response to treatment and dogs often crossed over between groups. Data within these studies 543 
often were not reported completely or summarized. 544 
25. Synthesis of results Objective 2 -Prevalence of parasitological cure after treatment 545 
We did not synthesize the data into a summary measure for two reasons. First, the working group did 546 
not specify a comparison of interest, instead indicating that they preferred to have results from any 547 
treatment used. Second, the working group also indicated that the proportions of cures were of interest, 548 
rather than a comparison such as a risk ratio or odds ratio of cure. It might seem sensible therefore to 549 
combine the estimates of proportions of cures; however, this was not possible for two reasons, one 550 
practical and one theoretical. The practical reason for not calculating summary “proportion of cures” is 551 
the extreme heterogeneity meant that it was not sensible to synthesize data and provide a summary 552 
estimate of efficacy. The 2
nd
 theoretical reason not to combine these data is that treatments should be 553 
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compared relatively to enable control of baseline levels of recovery, so a summary proportion would 554 
not be appropriate.   555 
26. Risk of bias across studies Objective 2 -Prevalence of parasitological cure after 556 
treatment) 557 
It was not possible to quantitatively assess the risk of bias due to small studies, because no single 558 
comparison was available for plotting. However, overall we would propose that in the opinion of the 559 
review team the risk of bias was low to medium overall for the studies that used-PCR based methods 560 
to assess the outcome. For studies that used xenodiagnostic approaches, the risk of bias is high, mainly 561 
because of the absence of information about allocation methods. For studies that looked at parasite 562 
load, the opinion of the review team was that the failure to ensure methods of assessing the load were 563 
blinded to animal status was a major source of bias.   564 
27. Additional analyses for Objective 2 -Prevalence of parasitological cure after treatment 565 
   No additional analyses were conducted.  566 
28. Study selection for Objective 3-Identifying challenge studies that might report 567 
diagnostic test characteristics (PCR, ELISA, IFAT) 568 
The number of citations available for Objective 3 was 3,865. Based on the protocol, we used text-569 
based searching of the abstract and title in EndNote ® to identify challenge studies.  The term 570 
“challenge” retrieved 73 citations, the term “experiment” retrieved 411 citations and the term 571 
“induced” retrieved 98 citations.  We combined these groups and after removing duplicates had 513 572 
citations. We then searched for articles that were published after and including 1990 (283 citations). 573 
We screened those abstracts, excluding based on the abstract citations that were obviously not 574 
relevant, for example murine and hamster models of Leishmania. We also excluded several citations 575 
based on the abstract when the language of the full-text publication was not English.  We obtained the 576 
full text of 169 articles. Sixty-two articles described at least one of the assays requested (PCR, ELISA 577 
or IFAT – without specifics of target) and 18 articles described the use of a PCR and either ELISA 578 
and/or IFAT. In assessing the PCR and ELISA, we did not exclude articles if the target was not clear. 579 
Many articles were not specific about the targets for the PCR, and the working group did not indicate 580 
that they were interested in a specific target for the ELISA (i.e., SLA or K 39 and children). 581 
DISCUSSION 582 
29. Summary of evidence for Objective 1 -Sensitivity and specificity of diagnostic assays in 583 
naïve dog populations 584 
Overall, the data available from the studies of naïve dogs has limited utility because of the absence of 585 
a gold standard diagnostic test for the detection of Canine leishmaniosis (CanL) caused by infection 586 
with Leishmania infantum, and all estimates are relative. Also, although described as longitudinal 587 
studies, the data are a series of cross sectional studies with changing prevalence. As such, it is not 588 
surprising that as apparent prevalence increases so does sensitivity.  589 
30. Limitations of Objective 1 -Sensitivity and specificity of diagnostic assays in naïve dog 590 
populations 591 
The absence of a gold standard, latent class methods or a mixed-treatment comparison meta-analysis 592 
make it difficult to reach conclusions about the assays. Clearly it would be preferable to conduct a 593 
review that used a gold standard or at least had a defined pairwise comparison when no gold standard 594 
exists.    595 
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31. Conclusions for Objective 1 -Sensitivity and specificity of diagnostic assays in naïve dog 596 
populations) 597 
There is a large amount of data available for the conduct of a review of diagnostic tests for Canine 598 
leishmaniosis (CanL); however, meta-analyses and interpretation is complicated by the absence of a 599 
gold standard and consistent use of relative measures of sensitivity and specificity by the primary 600 
research. If available, studies that use approaches to assessing non-gold standard settings could be used 601 
in a meta-analysis; however, none were identified in the relevant studies.  Numerous approaches to 602 
defining the scope of the review were discussed based on the time and resources available, and the 603 
final decision was made to limit the review to studies of naïve dogs. These studies represent a series of 604 
cross- sectional studies with changing prevalence, and although useful for estimating infection 605 
pressure, it is unclear to the review team for meta-analysis how the use of naïve dogs solves the issue 606 
of relative estimates as compared to studies with estimates obtained from a single point in time. In the 607 
review team’s opinion, unless a specific pairwise comparison could be identified that was of interest 608 
and a specific referent test agreed upon, it would be necessary to conduct a network meta-analysis of 609 
diagnostic tests; however, such approaches are poorly (or not) developed and would need development 610 
and validation of the underlying statistical method which is beyond the scope of this project.  611 
32. Summary of evidence for Objective 2 -Prevalence of parasitological cure after 612 
treatment 613 
Overall the data suggest that treatment results in less than 50% cure after 180 to 360 days of follow-614 
up. The treatments received were very varied so overall conclusions are limited.  615 
33. Limitations of Objective 2 -Prevalence of parasitological cure after treatment 616 
One of the major limitations of the data available for the review is the absence of studies suited to a 617 
specific PICO question that would allow estimation of comparative efficacy. Comparative efficacy is 618 
the preferred way to summarize treatment comparisons and is measured by metrics such as risk ratio, 619 
rate ratio or mean difference. It had originally been proposed to conduct a PICO format review but 620 
during the development of the protocol it was communicated that the working group was concerned 621 
that such a format i.e. one that limited the review to specific treatment regimes and comparative 622 
efficacy was not feasible. This concern was based on the working groups familiarity with the studies 623 
available. Given this expert knowledge, the working group proposed instead collection of the cure risk 624 
for every treatment option.  The approach therefore was modified to make the cure risk a population 625 
characteristic using any regime for the three drugs of interest. Based on this concept, the review 626 
protocol was redesigned as a PIT question i.e. a question about the cure risk in treated dogs. The major 627 
limitations with respect to inference were discussed but the final decision to use a PIT format was a 628 
pragmatic one.  Given the final data available, the working group correctly anticipated the type of data 629 
available, and if a PICO review had been conducted, every treatment regime would have had one 630 
observation. The enormous heterogeneity of populations and interventions would have precluded 631 
combining data meaningfully.  632 
34. Conclusions for Objective 2 -Prevalence of parasitological cure after treatment 633 
The data suggest that after long periods of treatment and after long periods of follow-up, several 634 
therapies have been associated with being unable to detect the organism in treated dogs. However no 635 
studies reported 100% cure risks at the end of the follow-up periods, which varied between 180 and 636 
720 days.   637 
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TABLES 639 
Table 1 Number of records retrieved by information source  640 
Information source  Number of records identified  
Science Citation Index (SCI) 1,594 
Conference Proceedings Citation Index – Science (CPCI-S) 101 
CAB Abstracts  2,815 
BIOSIS Citation Index  1,352 
MEDLINE and MEDLINE In-Process 1,525 
Open Grey  18 
Total  7,405 
Total without duplicates  3,865 
 Scoping review and protocols for 
Canine Leishmania  
 
Supporting publications 2015:EN-761 20 
   
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food 
Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an 
output adopted by the Authority. The European food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the 
rights of the authors. 
 
Table 2 Description of 11 studies identified as potential longitudinal studies but excluded after full-text screening 641 
 642 
Citation Rationale for exclusion 
(Baldelli et al., 2011) Animals in the study were only evaluated using serology. Some animals were tested using PCR on bone marrow but the authors 
only tested the serology-positive animals with BM PCR. 
(Dye et al., 1993) Although the dogs are likely naïve as they were introduced into the kennel area, the testing approaches used during the study 
consisted only of serology based on IFAT. 
(Fisa et al., 1999) Not a longitudinal study, rather a series of cross-sectional surveys conducted in an endemic area. 
(Madany et al., 2004) Only the abstract is available and it does not mention the use of PCR, so excluded. 
(Mansueto et al., 1982) Excluded because it was published prior to 1990 so not likely to have PCR results. 
(Marty et al., 1988) Excluded because it was published in 1988 and therefore does not meet the cut-off date of 1990. 
(Mekuzas et al., 2009) Excluded because this study was published in 1973 and therefore does not have a post-1990 PCR assay. 
(Mitali et al., 1999) Study does not report the use of PCR as an approach to screening the dogs either at the beginning or during the study.  
(Otranto et al., 2007) This study uses an immunochromatographic dipstick test and the working group asked only for IFAT and ELISA. Other 
serological assays were not asked for as per the protocol. 
(Paradies et al., 2010) Paper not published in English. 
(Vidor et al., 1991) Study does not appear to use PCR. The full paper is not available in English. 
  643 
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Table 3 Study characteristics of the 7 studies that used naïve dogs in longitudinal studies to evaluate diagnostic tests for the detection of Leishmania 644 
infection 645 
Citation Study year Country Source of dogs Initial tests for naiveté 
(Gramiccia et al., 2010) 2008 Italy Local strays PCR, IFAT 
(Hamel et al., 2013) 2009 Germany Local client-owned PCR, IFAT 
(Leandro et al., 2001) NR NR Experimental beagles Laboratory dogs 
(Oliva et al., 2006) 2002 Italy Imported dogs PCR, IFAT, Other 
(Otranto et al., 2013) 2011 Italy Local strays PCR, IFAT 
(Otranto et al., 2009) 2005 Italy Local client-owned PCR, ELISA, IFAT, Other 
(Otranto et al., 2010) 2008 Italy Local strays, laboratory/experimental PCR, IFAT, Other 
 646 
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Table 4 Characteristics of diagnostic tests used in 7 longitudinal studies that used naïve dogs to evaluate diagnostic tests for the detection of Leishmania 648 
infection 649 
Citation PCR description ELISA description IFAT description IFAT cut-
off 
(Gramiccia 
et al., 
2010) 
For the n-PCR assay, the ﬁrst ampliﬁcation was 
carried out in a 50 l volume containing 10 l DNA 
plus 40 l PCR Master Mix (Promega) containing 
50 pmol of the kinetoplastid-speciﬁc primers R221 
and R332 of the small subunit rRNA gene (van Eys 
et al., 1992). For the second ampliﬁcation, 3 l of 
the ﬁrst PCR product were added to 22 l of PCR 
Master Mix (Promega) containing 3 pmol of the 
Leishmania-speciﬁc primers R223 and R333 of the 
same gene (van Eys et al., 1992). In canine assays, 
2 negative (no DNA, and buffy coat (BC) DNA 
from healthy dogs) and 2 positive controls (DNA 
from L. infantum cultured promastigotes and BC 
DNA from Leishmania-infected dogs) were 
employed. Ampliﬁcation products were analyzed 
on 1.5% agarose gel and visualized under UV light. 
Positive samples yielded a predicted n-PCR 
product of 358 bp. Contamination of amplicons 
was avoided by using physical separation (rooms 
and materials) as well as decontamination 
procedures (UV exposure and bleaching of 
materials and surfaces). To exclude false-negative 
results due to scarce sample material, low DNA 
extraction efﬁciency, or the presence of PCR 
inhibitors, a random subset (approximately 10% of 
the total) of canine DNA samples resulted n-PCR-
negative were submitted to conventional PCR for 
the ampliﬁcation of the 181 bp fragment of the 
canine glyceraldehyde-3-phosphate dehydrogenase 
 The in-house IFAT antigen consisted of cultured 
promastigotes of the WHO reference strain for L. 
infantum zymodeme MON-1 
(MHOM/TN/80/IPT-1). The assay procedure 
followed the protocol recommended by the Ofﬁce 
International des Epizooties (OIE, 2000). A low 
cut-off dilution (1/80) was set for the selection of 
cohort (A) dogs, aiming to include full 
seronegative animals for follow-up samplings. For 
all other determinations, the IFAT cut-off titre 
was set at 1/160 as per standard operational 
protocol applied for dog examination at kennel 
entry.  
1/80 
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gene, using primers and conditions reported by 
Ramiro et al. (2003). 
(Hamel et 
al., 2013) 
Real-time PCRs were used for the detection of 
Leishmania spp. - and E. canis-DNA [15, Silaghi 
et al., unpublished]. 
 An in-house Leishmania spp.-IFAT was used for 
the detection of anti-Leishmania spp.-antibodies. 
NR 
(Leandro 
et al., 
2001) 
Parasite’s DNA was detected by polymerase chain 
reaction (PCR) according to Campion et al. (2000), 
from popliteal lymph node, bone marrow and skin 
tissue. 
Parasite-specific antibodies were 
determined by ELISA.  ELISA, for 
total anti-Leishmania antibodies, 
was performed according to Voller 
et al. (1976) and modified using 
the conjugate protein A-HRP 
(Biorad, Hercules, USA). The 
optical density of 0.180 was 
considered the limiting titre. 
  
(Oliva et 
al., 2006) 
Total genomic DNA was extracted from 350 l of 
BM sample 
using the Easy-DNA kit (Invitrogen, San Diego, 
CA) and was stored at 20°C until use. The first 
PCR amplification was carried out in a 50-l volume 
containing 10 l BM DNA plus 40 l PCR Master 
Mix (Promega) containing 50pmol of the 
kinetoplastid-specific primers R221 and R332 of 
the small-subunit rRNA gene (27). For the second 
amplification, 3 l of the first PCR product was 
added to 22 l of PCR Master Mix (Promega) 
containing 3 pmol of the Leishmania-specific 
primers R223 and R333 of the same gene  
 The in-house antigen consisted of promastigotes 
of L. infantum zymodeme MON-1, and the assay 
procedure followed the protocol of the Office 
International des Epizooties (9). The cut-off 
dilution was set at 1:160. 
1:160 
(Otranto et 
al., 2013) 
PCR for the amplification of Leishmania DNA was 
performed on bone marrow, conjunctival swab and 
skin samples. Total DNA was extracted using the 
QIAampDNA Micro Kit (Qiagen, GmbH, Hilden, 
Germany) and the Genomic DNA Purification Kit 
(Gentra Systems, Minnesota, USA), respectively, 
and a fragment of L. infantum kinetoplast DNA 
 An indirect immunofluorescent antibody test 
(IFAT) was performed using promastigotes of L. 
infantum zymodeme MON1 as antigen as 
described elsewhere [19]. Samples were scored 
positive when a clear cytoplasmic or membrane 
fluorescence with promastigotes could be 
observed using a cut-off dilution of 1:80; positive 
1:80 
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minicircle was amplified using the MC1/MC2 
primer set [14]. Amplicons were resolved in 
ethidium bromide-stained (2%) agarose gels 
(Gellyphor, Italy) and sized by comparison with 
markers in the Gene Ruler
TM
 100 bp DNA 
Ladder (MBI Fermentas, Lithuania). Gels were 
photographed using a digital documentation system 
(Gel Doc 2000, BioRad, UK). 
sera were titrated until negative. 
(Otranto et 
al., 2009) 
One skin sample weighing about 30 mg per animal 
and per collection time was taken from the right 
shoulder region by using a disposable 
ophthalmology scalpel after the hair over an area of 
about 0.5 by 0.5 cm was clipped. The samples were 
stored at 20°C in Eppendorf tubes containing 1 ml 
of phosphate-buffered saline. After disruption in 
liquid nitrogen and pestling (i.e., two freeze-thaw 
cycles), genomic DNA was extracted from the 
approximately 30-mg skin samples by using a 
commercial kit (genomic DNA puriﬁcation kit; 
Gentra Systems). An L. infantum kinetoplastid 
minicircle DNA fragment was ampliﬁed with the 
MC1MC2 primer pair (6). Genomic DNA solution 
(4  l) was added to the PCR mixture (46  l), which 
contained 2.5 mM MgCl 2 , 10 mM Tris-HCl (pH 
8.3), 50 mM KCl, 250  M of each deoxynucleoside 
triphosphate, 50 pmol of each primer, and 1.25 U 
of Ampli Taq Gold (Applied Biosystems, Milan, 
Italy). Optimal conditions for PCR ampliﬁcation 
were standardized as follows: initial denaturation at 
94°C for 12 min; 30 cycles consisting of 
denaturation at 94°C for 30 s, annealing at 60°C 
for 20 s, and extension at 72°C for 30 s; and a ﬁnal 
extension at 72°C for 5 min. A positive control 
containing genomic L. infantum DNA and a 
The ELISA was performed by 
using water-soluble proteins of 
promastigote forms of L. infantum 
(zymodeme MON1) as antigens 
and goat anti-dog IgG antibodies 
(gamma chain speciﬁc) conjugated 
to alkaline phosphatase 
(Kirkegaard & Perry Laboratories, 
Inc., Gaithersburg, MD) as 
detection antibodies. Samples were 
considered positive if the 
absorbance at 405 nm (A 405) was 
above the arithmetic mean plus 3 
standard deviations of the A 405 
values for 48 Leishmania control 
dogs originating from an area in 
southern Switzerland free of L. 
infantum, E. canis, and Babesia 
canis (21). The results were 
expressed as a system of arbitrary 
antibody units (AU), where 0 AU 
corresponds to the threshold value 
and 100 AU corresponds to the 
result for the positive standard 
serum sample. 
IFAT was performed with promastigotes of L. 
infantum zymodeme MON1 as the antigen. The 
cells were exposed to sera diluted (1:80) in 
phosphate-buffered saline in a moist chamber and 
then to ﬂuoresceinated rabbit anti-dog 
immunoglobulin G (IgG) serum diluted 1:40 
(rabbit anti-dog IgG; lot 125K4752; Sigma-
Aldrich Chemie, Germany); each exposure was at 
37°C for 30 min. The samples were scored 
positive when they produced a clear cytoplasmic 
or membrane ﬂuorescence with promastigotes by 
use of a cut-off dilution of 1:80. Positive sera 
were titrated until they gave negative results. 
1:80 
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negative control without DNA were included in all 
the assays. Ampliﬁcation products (447 bp) were 
visualized on 2% (wt/vol) agarose gels (Ambion, 
Milan, Italy) upon staining with ethidium bromide. 
(Otranto et 
al., 2010) 
DNA was extracted from 100 µl of bone marrow 
using the QIAamp DNA microkit (Qiagen, Milan, 
Italy) and from about 50 mg of skin samples using 
a genomic DNA puriﬁcation kit (Gentra Systems, 
Minneapolis, MN), following the producers’ 
recommendations. A fragment (447 bp) of the L. 
infantum minicircle kinetoplast DNA (kDNA) was 
ampliﬁed using the primers MC1 and MC2 (5). 
The sample DNA (4  l) was added to the PCR mix 
(46  l) containing 2.5 mM MgCl 2, 10 mM Tris-
HCl, pH 8.3, and 50 mM KCl, 250  M (each) 
deoxynucleoside triphosphates (dNTPs), 50 pmol 
of each primer, and 1.25 U of AmpliTaq Gold 
polymerase (Applied Biosystems, Milan, Italy). 
PCR conditions were standardized as follows: 
initial denaturation at 94°C for 12 min, 30 cycles 
consisting of denaturation at 94°C for 30 s, 
annealing at 60°C for 20 s, extension at 72°C for 
30 s, and a ﬁnal extension at 72°C for 5 min. 
Positive (L. infantum DNA) and negative (no 
DNA) controls were included in all the assays. 
Ampliﬁcation products were visualized by 2% 
agarose gel electrophoresis under UV exposure. 
 An in-house immunoﬂuorescent antibody test 
(IFAT) was used to detect anti-Leishmania IgG 
antibodies. Promastigotes of L. infantum 
zymodeme MON-1 were used as an antigen, and 
all procedures were performed as described 
elsewhere (29). Samples were scored as positive 
when they produced a clear cytoplasmic or 
membrane ﬂuorescence with promastigotes using 
a cut-off dilution of 1:80. Positive sera were 
titrated until negative. 
1:80 
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Table 5 Risk of bias in 7 longitudinal studies that used naïve dogs to evaluate diagnostic tests for the detection of Leishmania infection (see appendix E. 651 
for the risk of bias (ROB) questions and interpretation).  652 
Risk of bias domain (Gramiccia et 
al., 2010) 
(Hamel 
et al., 
2013) 
(Leandro et al., 
2001) 
(Oliva et al., 2006) (Otranto et 
al., 2013) 
(Otranto et 
al., 2009) 
(Otranto 
et al., 
2010) 
Representative spectrum? Not discernible Yes No Not discernible Not 
discernible 
Not 
discernible 
Not 
discernible 
ROB -- Representative spectrum Unclear Low High Unclear Unclear Unclear Unclear 
Notes: representative spectrum no notes no notes no notes Dogs kept in kennel 
situation 
Kennel/shelte
r situation 
No notes no notes 
Acceptable reference standard? No No Not discernible No Yes No Yes 
ROB -- Acceptable reference standard High High High Unclear Low High Low 
Notes: acceptable reference standard No notes No notes Did not seem to be a 
kDNA assay based 
on description in 
reference paper.
a
  
The dogs were from 
a non-endemic area, 
so should have been 
naïve, given they 
were seronegative on 
IFAT 
No notes No notes No notes 
Acceptable delay between tests? Yes Yes Yes Yes Yes No/Not 
discernible 
Yes 
ROB -- Acceptable delay between tests Low Low Low Low Low Unclear Low 
Notes: acceptable delay between tests Assumed run 
concurrently 
Assumed 
run 
concurre
ntly 
Assumed run 
concurrently 
Assumed run 
concurrently 
Assumed run 
concurrently 
Assumed run 
concurrently 
Assumed 
run 
concurrentl
y 
Partial verification avoided? No/Not 
discernible 
Yes Yes Yes Yes No/Not 
discernible 
Yes 
ROB -- Partial verification avoided Unclear Low Low Low Low High Low 
Notes: partial verification avoided The original 
sample of dogs 
were likely not 
No notes No notes No notes No notes Many 
withdrawals 
not tested at 
no notes 
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all naïve (only 
tested with 
conjunctival 
PCR, not bone 
marrow or 
buffy coat). 
The dogs 
identified in 
July 2008 by 
buffy coat PCR 
as positive 
were all 
followed 
subsequently. 
all follow-up 
times 
Differential verification avoided? Yes Yes Yes Yes Yes Yes Yes 
ROB -- Differential verification avoided Low Low Low Low Low Low Low 
Notes: differential verification avoided This is 
assuming the 
referent was the 
BM PCR (not 
the skin PCR) 
No notes No notes No notes No notes No notes No notes 
Incorporation of tests avoided? Yes Yes No/Not discernible Yes Yes Yes Yes 
ROB -- Incorporation of tests avoided Low Low High Low Low Low Low 
Reference testing blinded? No/Not 
reported 
No/Not 
reported 
No/Not reported No/Not reported No/Not 
reported 
No/Not 
reported 
No/Not 
reported 
ROB -- Reference testing blinded Unclear High High High High High Unclear 
Notes: index test results blinded No notes No notes No notes No notes Lab 
personnel 
blinded to 
treatment 
group, but 
not 
No notes No notes 
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necessarily to 
previous test 
results 
Index testing blinded? No/Not 
discernible 
No/Not 
discernib
le 
No/Not discernible No/Not discernible No/Not 
discernible 
No/Not 
discernible 
No/Not 
discernible 
ROB -- Index testing blinded Unclear High High High High High Unclear 
Notes: reference test results blinded no notes no notes no notes no notes Lab 
personnel 
blinded to 
treatment 
group, but 
not 
necessarily to 
previous test 
results 
no notes no notes 
Intermediate/uninterpretable test results 
reported? 
Not discussed Not 
discusse
d 
Not discussed Not discussed Not 
discussed 
Yes Not 
discussed 
ROB -- Intermediate/uninterpretable test 
results reported 
Unclear Unclear Unclear Unclear Unclear Low Unclear 
Withdrawals explained? Yes >10% 
loss to 
follow-
up 
>10% loss to follow-
up 
Yes Yes >10% loss to 
follow-up 
>10% loss 
to follow-
up 
ROB -- Withdrawals explained Low High Low Low Low High High 
Notes: withdrawals This is for the 
17 group B 
dogs (there 
were no losses 
to follow-up) 
No notes No notes No notes No notes No notes Withdrawa
ls were not 
discussed 
anywhere 
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a  Detection of parasite DNA by PCR: 1-2mm3 of the canine tissues were collected and digested overnight at 60C in 200 ml lysis buffer (50mM NaCl, 50mM Tris-HCl pH 8.0, 10mM EDTA) 654 
containing 20% SDS and 200 mg/ml proteinase K. Following phenol/ chloroform extraction and ethanol precipitation, the DNA was re-suspended in 50-ml ultra-pure water. PCR amplification 655 
was carried out in 25 ml solution containing 50mM KCl, 10mM Tris-HCl pH 8.0, 4mM MgCl2, 50 pmol of each primer, 200mmol of deoxynucleotides, 1.25U Taq polymerase and 5 ml of 656 
DNA, for 38 cycles in a Perkin–Elmer Cetus 480® thermal cycler. Each cycle consisted of denaturation at 94C (10 1500), annealing at 60C (10), and extension at 72C (20). The PCRs were 657 
performed using primers derived from the small sub-unit rRNA sequence (50GGTTCCTTTCCTGATTTACG30 and 50GGCCGGTAAAGGCCGAATAG30) which amplify all types of 658 
Leishmania (Van Eys et al., 1992). Inhibition of the reaction, or degradation of DNA, was controlled subjecting 5ml of each DNA sample to a PCR using primers from the canine b-actin gene 659 
(50TCCTCCCTGGAGAAGAGC30 and 50ATCTCCTTCTGCATCCTG30) under the same conditions as described above. The PCR products were analyzed by 2% agarose gel electrophoresis, 660 
with a 100 bp DNA ladder used as a marker. Samples showing a 600 bp PCR product were scored as positive.
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Table 6 Individual study results for 7 studies of naïve dogs included in the evaluation of diagnostic tests 662 
 663 
Longitudinal study on the detection of canine Leishmania infections by conjunctival swab analysis and correlation with entomological parameters (Gramiccia et 
al., 2010)  
Definition of naïve dogs: Negative on conjunctival swab PCR and IFAT in February 2008 
Date of 
follow-up 
test (Month, 
year) 
Number 
of dogs 
tested at 
time point 
Number of dogs 
test positive with 
“gold standard” 
(GS) 
 
PCR (Buffy coat) 
PCR1 (Conjunctiva)  PCR2  IFAT ELISA 
GS+ and 
PCR1+ 
(relative 
sensitivity) 
GS– and 
PCR–
(relative 
specificity) 
GS+ and 
PCR2+ 
(relative 
sensitivity) 
GS– and 
PCR2– 
(relative 
specificity) 
GS+ and 
IFAT+ 
(relative 
sensitivity) 
GS– and 
IFAT– 
(relative 
specificity) 
GS+ and 
ELISA+ 
(relative 
sensitivity) 
GS– and 
ELISA– 
(relative 
specificity) 
July 2008 17 17 0 (0%) - - - - - - - 
September 
2008 
17 17 0 (0%) - - - - - - - 
November 
2008 
17 6 0 (0%) - - - 0 (0%) - - - 
May 2009 17 3 3 (100%) - - - 0 (0%) - - - 
Prevention of Canine Leishmaniosis in a Hyper-Endemic Area Using a Combination of 10% Imidacloprid/4.5% Flumethrin (Otranto et al., 2013)  
Definition of naïve dogs: Negative on skin, bone marrow and conjunctival swab PCR and IFAT in March-April 2011 
Date of 
follow-up 
test (Month, 
year) 
Number 
of dogs 
tested at 
time point 
Number of dogs 
test positive with 
“gold standard” 
(GS) 
 
PCR (skin) 
PCR1 (Bone marrow)  PCR2 (conjunctiva)  IFAT ELISA 
GS+ and 
PCR1+ 
(relative 
sensitivity) 
GS– and 
PCR–
(relative 
specificity) 
GS+ and 
PCR2+ 
(relative 
sensitivity) 
GS– and 
PCR2– 
(relative 
specificity) 
GS+ and 
IFAT+ 
(relative 
sensitivity) 
GS– and 
IFAT– 
(relative 
specificity) 
GS+ and 
ELISA+ 
(relative 
sensitivity) 
GS– and 
ELISA– 
(relative 
specificity) 
Nov.  2011 21 7 -  -  7 (100%)  -  
March 2012 21 11 6 (54.5%)  4 (36%)  8 (73%)  -  
Arthropod-borne infections in travelled dogs in Europe (Hamel et al., 2013) 
Definition of naïve dogs:  Dogs that lived in Germany and travelled to leishmania-infected areas. Tested negative before travel based on IFAT and blood-based 
PCR  
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Date of 
follow-up 
test (Month, 
year) 
Number 
of dogs 
tested at 
time point 
Number of dogs 
test positive with 
“gold standard” 
(GS) 
 
PCR (blood) 
PCR1  PCR2 () IFAT ELISA 
GS+ and 
PCR1+ 
(relative 
sensitivity) 
GS– and 
PCR–
(relative 
specificity) 
GS+ and 
PCR2+ 
(relative 
sensitivity) 
GS– and 
PCR2– 
(relative 
specificity) 
GS+ and 
IFAT+ 
(relative 
sensitivity) 
GS– and 
IFAT– 
(relative 
specificity) 
GS+ and 
ELISA+ 
(relative 
sensitivity) 
GS– and 
ELISA– 
(relative 
specificity) 
1
st
 post 
travel (4-373 
days after 
return (mean 
38 days)) 
106 0/106 - - - - - 103 (97%) - - 
Cell-mediated immunity and specific IgG1 and IgG2 antibody response in natural and experimental canine leishmaniosis (Leandro et al., 2001) 
Definition of naïve dogs: Not specifically stated; however, experimental animals were used and tested by ELISA and lymphocyte proliferation to crude L. 
infantum antigen prior to the start of the study  
Date of 
follow-up 
test (Month, 
year) 
Number 
of dogs 
tested at 
time point 
Number of dogs 
test positive with 
“gold standard” 
(GS) 
 
PCR 
PCR1 () PCR2 () IFAT ELISA 
GS+ and 
PCR1+ 
(relative 
sensitivity) 
GS– and 
PCR–
(relative 
specificity) 
GS+ and 
PCR2+ 
(relative 
sensitivity) 
GS– and 
PCR2– 
(relative 
specificity) 
GS+ and 
IFAT+ 
(relative 
sensitivity) 
GS– and 
IFAT– 
(relative 
specificity) 
GS+ and 
ELISA+ 
(relative 
sensitivity) 
GS– and 
ELISA– 
(relative 
specificity) 
1-16 months 3 Not reported in a manner that enabled assessment. The authors stated “Parasites were detected from lymph nodes or bone marrow and skin 
biopsies in the three dogs” however it is unclear if this is based on PCR or culture or describes cumulative results of monthly outcomes. 
           
Incidence and time course of Leishmania infantum infections examined by parasitological, serologic, and nested-PCR techniques in a cohort of naïve dogs exposed 
to three consecutive transmission seasons (Oliva et al., 2006) 
Definition of naïve dogs:  Beagles born in an area of northern Italy where the infection is not endemic and which tested Leishmania-negative by serology 
(immunofluorescent-antibody test [IFAT]), were moved to the study site in July 2002. 
Date of 
follow-up 
test (month, 
year) 
Number 
of dogs 
tested at 
time point 
Number of dogs 
test 
positive/negative 
with “gold 
standard” (GS) 
 
PCR1 () PCR2 () IFAT ELISA 
GS+ and 
PCR1+ 
(relative 
sensitivity) 
GS– and 
PCR–
(relative 
specificity) 
GS+ and 
PCR2+ 
(relative 
sensitivity) 
GS– and 
PCR2– 
(relative 
specificity) 
GS+ and 
IFAT+ 
(relative 
sensitivity) 
GS– and 
IFAT– 
(relative 
specificity) 
GS+ and 
ELISA+ 
(relative 
sensitivity) 
GS– and 
ELISA– 
(relative 
specificity) 
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PCR (bone 
marrow) 
March 2003 43 10/33 - - - - 3 (30%) 33 (100%) - - 
Sept. 2003 42 14/28 - - - - 3 (21.4%) 28 (100%) - - 
Dec. 2003  40 19/21 - - - - 3 (15.8%) 21 (100%) - - 
March. 2004  39 26/13 - - - - 9 (34.6%) 13 (100%) - - 
May 2004 38 33/5     18 (54.5%) 5 (100%)   
Dec. 2004 37 35/2 - - - - 27 (77.1%) 2 (100%) - - 
May 2005 37 36/1 - - - - 28 (77.8%) 1 (100%) - - 
Toward diagnosing Leishmania infantum infection in asymptomatic dogs in an area where leishmaniasis is endemic. (Otranto et al., 2009) 
Definition of naïve dogs: Negative on IFAT, ELISA, stained lymph node smears and skin PCR in January and February 2005 
Date of 
follow-up 
test (Month, 
year) 
Number 
of dogs 
tested at 
time point 
Number of dogs 
test 
positive/negative 
with “gold 
standard” (GS) 
 
PCR (skin) 
PCR1 () PCR2 () IFAT ELISA 
GS+ and 
PCR1+ 
(relative 
sensitivity) 
GS– and 
PCR–
(relative 
specificity) 
GS+ and 
PCR2+ 
(relative 
sensitivity) 
GS– and 
PCR2– 
(relative 
specificity) 
GS+ and 
IFAT+ 
(relative 
sensitivity) 
GS– and 
IFAT– 
(relative 
specificity) 
GS+ and 
ELISA+ 
(relative 
sensitivity) 
GS– and 
ELISA– 
(relative 
specificity) 
 November 
2005 
NR
^
 14/? — — — — 2 (14%) NR (99%)^ 1* (7%) NR (95%)^ 
March 2006 NR 11/? — — — — 3 (27%) NR (99%)^ 1* (50%) NR 
(95.5%)^ 
March 2007 NR 23/? 
¶
 — — — — 2 (13%) NR (92%)^ 3 (9%) NR (93%)^ 
 * The authors report in Table 4 that the sensitivity is 33%. However, the text says “11 dogs positive on PCR only, and 3 parasitological and serology positive”. 
The authors do not clarify if the positive serology is ELISA or IFAT. Based on Table 5, it appears that only 1 of those 3 serological/parasitology positive was 
positive on ELISA therefore our estimate of sensitivity is 1/14 (7%). We were unable to verify the percentages reported in Table 4, as the authors did not report 
numbers, only percentages. The same issue was repeated for March 2006 and March 2007 data. Note that our approach to verifying the IFAT data did correspond 
with the authors’ data in Table 4. Also note that Table 4 had a large number of superscripts without any legends or footnotes.  
 ^ The number of animals tested at each time point is not clear. The authors do not clarify if all dogs available at the time were used to obtain estimates or if only 
dogs with complete data were used (173) to estimate the data in Table 4.  
 
¶ 
Dead dog excluded. 
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Diagnosis of canine vector-borne diseases in young dogs: a longitudinal study (Otranto et al., 2010) 
Definition of naïve dogs: Negative on all cytology, IFAT, PCR skin, and PCR bone marrow 
Date of 
follow-up 
test (Month, 
year) 
Number 
of dogs 
tested at 
time point 
Number of dogs 
test 
positive/negative 
with “gold 
standard” (GS) 
 
PCR (skin) 
PCR1 () PCR2 () IFAT ELISA 
GS+ and 
PCR1+ 
(relative 
sensitivity) 
GS– and 
PCR–
(relative 
specificity) 
GS+ and 
PCR2+ 
(relative 
sensitivity) 
GS– and 
PCR2– 
(relative 
specificity) 
GS+ and 
IFAT+ 
(relative 
sensitivity) 
GS– and 
IFAT– 
(relative 
specificity) 
GS+ and 
ELISA+ 
(relative 
sensitivity) 
GS– and 
ELISA– 
(relative 
specificity) 
July 39 0/39     NA 39 (100%)   
October 
2008 
46 1/45 — — — — NR (0%) NR (87%) — — 
April 2009 PCR skin 
42; PCR 
bone 
marrow 
44; IFAT 
42 
3 NR (67%) NR (100%) — — NR (100%) NR (58.5%) — — 
 664 
* EFSA did not define a gold standard so if the study authors defined a gold standard that was used. If the study authors did not define a gold standard, we used the PCR if only one was used, or 665 
if multiple PCR assays were used we used the assay most frequently used; if multiple PCR assays were used with equal frequency we selected the gold standard in the following order: bone 666 
marrow, blood, skin, lymph node, and conjunctiva.   667 
  668 
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 670 
Table 7 Description of 13 studies included in a review of studies comparing treatment efficacy of meglumine antimoniate, allopurinol, or miltefosine for 671 
Leishmania infection in dogs in Europe 672 
Author Title Year 
published 
Country Source of dogs Health status of dogs PCR used Xenodiagnosis 
used 
(Ariti et al., 
2013) 
Treatment of canine leishmaniasis: 
long-term molecular and serological 
observations 
2013 Italy Veterinary 
hospitals/client- 
owned dogs 
Clinically unwell See footnote
1
 None 
(Guarga et 
al., 2002) 
Evaluation of a specific 
immunochemotherapy for the 
treatment of canine visceral 
leishmaniasis 
2002 Spain Not discernible Clinically unwell None See footnote
2
 
(Miro et al., 
2011) 
Infectivity to Phlebotomus 
perniciosus of dogs naturally 
parasitized with Leishmania 
infantum after different treatments 
2011 Spain Veterinary 
hospitals/client- 
owned dogs 
Clinically unwell None See footnote
3
 
                                                     
1 "PCR for Leishmania sp. was performed as previously described." Blood, conjunctiva, and lymph node samples used. From supplementary paper: "…DNA hybridization methods through the 
amplification of the minicircle target sequence. The oligonucleotide primers used are able to direct the amplification of all Leishmania strains tested." 
2 “The handling of the animals and the vectors was carried out in an insectarium conditioned according to the recommendations of ‘‘The Subcommittee on Arbovirus Laboratory Safety of the 
American Committee on Arthropod-Borne Viruses, Centre for Disease Control, Atlanta, GA (Anon., 1980). In order to determine the infectiveness of the dogs on the sand ﬂies which fed on 
it, a colony of Phlebotomus perniciosus kept in laboratory conditions (Molina, 1991) was used. Brieﬂy, each dog was anaesthetised with 0.03 mg/kg of medetomidine hydrochloride 
(DOMTOR 1, SmithKline Beecham) and its head was introduced for 1 h in a cubic net made of ﬁne gauze and containing a group of 75 females sand ﬂies. The sand ﬂies were dissected 5 
days post-blood meal to detect the presence of Leishmania promastigotes in their middle gut. The percentages of infection were estimated with the number of existing females at the moment 
of dissection.” 
3 “The infectivity of dogs was assessed through direct xenodiagnosis. The local colony of P. perniciosus used in this study had been laboratory-reared at the Instituto de Salud Carlos III, Madrid 
[30]. The colony was kept in a chamber under controlled conditions of temperature (27-28°C), relative humidity (95-100%) and light cycle (17 hours light/7 hours dark). Dogs were sedated 
by the intravenous injection of 0.5 mg/kg of medetomidine and their heads introduced into individual cube-shaped nets (50 cm wide × 50 cm high × 50 cm deep). Before treatment (Day 0) 
and 60, 120, and 180 dpt onset, dogs were exposed for one hour to 100 unfed, 7-day-old female sand flies released inside the nets. After one hour of exposure, the sand flies were carefully 
collected using a mouth aspirator. Fed flies collected from each dog were separated into individual nets (15 × 15 × 15 cm). Next the dogs were removed from their cages and intravenously 
administered 0.25 mg/kg of atipamezole. Fed sand flies were kept inside the chambers for 5-7 days. Engorged females were dissected and the sand fly midgut was examined under a light 
microscope to detect L. infantum promastigotes.” 
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(Mateo et al., 
2009) 
Multicentric, controlled clinical 
study to evaluate effectiveness and 
safety of miltefosine and allopurinol 
for canine leishmaniosis 
2009 France, 
Italy, Spain 
Veterinary 
hospitals/client-
owned dogs 
Clinically unwell See footnote
4
 None 
(Moritz et al., 
1998) 
Clinical follow-up examination after 
treatment of canine leishmaniasis 
1998 Germany Veterinary 
hospitals/client-
owned dogs 
Clinically unwell “by  PCR  
method  
(peripheral 
blood/bone 
marrow)” 
None 
(Neogy et al., 
1994) 
Exploitation of parasite-derived 
antigen in therapeutic success against 
canine visceral leishmaniosis 
1994 France Veterinary 
hospitals/client-
owned dogs 
Clinically unwell None None 
(Oliva et al., 
1998) 
Comparative efficacy of meglumine 
antimoniate and aminosidine 
sulphate, alone or in combination, in 
canine leishmaniasis 
1998 Italy Not discernible Clinically unwell None None 
(Paradies et 
al., 2012) 
Monitoring the reverse to normal of 
clinico-pathological findings and the 
disease-free interval time using four 
different treatment protocols for 
canine leishmaniosis in an endemic 
area 
2012 Italy Veterinary 
hospitals/client-
owned dogs 
Clinically unwell None None 
(Pennisi et 
al., 2005) 
Efficacy of the treatment of dogs 
with leishmaniosis with a 
combination of metronidazole and 
spiramycin.[Erratum appears in Vet 
Rec. 2005 May 14;156(20):653] 
2005 Italy Not discernible Clinically unwell See footnote
5
 None 
                                                     
4 “The RTQ-PCR analysis of bone marrow aspirates was performed by the WHO Collaborating Centre for Leishmaniosis – Instituto de Salud Carlos III (Madrid, Spain). Quantiﬁcation of 
leishmanial DNA in the dogs studied was performed using LightCycler high speed thermal cycler and the LightCycler FastStart DNA Master SYBR Green I kit (Roche Diagnostics). PCR 
primers used for speciﬁc ampliﬁcation of Leishmania were R223 and R333. 20 Final volume of the reaction was 20 mL, including 4 mL of target DNA. Quantiﬁcation was by means of a 
standard curve which consisted of serial dilutions of L. infantum DNA (strain JPC, MCAN ⁄ ES ⁄ 98 ⁄ LLM-722), ranging from the equivalent to 10 5 parasites ⁄ mL up to 10) 1 parasites ⁄ 
mL. Melting peak analysis was performed to check the speciﬁcity of the PCR products.” 
5 “The PCR technique applied was that described by Reale and others (1999). The target DNA for amplification was a 116 base pair fragment in the constant region of the kDNA minicircle.” 
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(Plevraki et 
al., 2006) 
Effects of allopurinol treatment on 
the progression of chronic nephritis 
in canine leishmaniosis (Leishmania 
infantum) 
 
2006 Greece Veterinary 
hospitals/client-
owned dogs 
Clinically unwell “…bone 
marrow PCR 
was performed 
for the 
detection of L. 
infantum 
rRNA.” 
None 
(Saridomiche
lakis et al., 
2005) 
Periodic administration of 
allopurinol is not effective for the 
prevention of canine leishmaniosis ( 
Leishmania infantum) in the endemic 
areas 
 
2005 Greece Veterinary 
hospitals/client-
owned dogs 
Healthy/no clinical 
signs 
See footnote
6
 None 
(Slappendel 
and Teske, 
1997) 
The effect of intravenous or 
subcutaneous administration of 
meglumine antimonate (Glucantime) 
in dogs with leishmaniasis. A 
randomized clinical trial 
 
1997 Netherland
s 
Veterinary 
hospitals/client-
owned dogs 
Clinically unwell None None 
                                                     
6
 “An aliquot of each bone marrow sample served to amplify a 250 bp fragment of the rRNA gene of Leishmania spp. according to a validated PCR protocol (Koutinas et al., 2001; Leontides et 
al., 2002), where T2 and B4 primers were utilized (Minodier et al., 1997).” 
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(Steuber et 
al., 1998 
PCR follow-up examination after 
treatment of canine leishmaniosis 
(CaL) 
1998 Germany Veterinary 
hospitals/client-
owned dogs 
Not discernible See footnote
7
 None 
(Steuber et 
al., 1998) 
       
 673 
                                                     
7 “DNA was standardized using the QIAamp Blood Kit ® (Qiagen, Germany) for cleanup. For the detection of genomic Leishmania DNA, the PCR procedure described by Piarroux et al. [23] 
was used. This procedure permitted the identification of a highly repetitive 100 bp sequence of Leishmania infantum. For each run, a total volume of 50μL was used consisting of 10μL of 
extracted specimen DNA, 0.2 mM each of dNTP (dUTP, dATP, dCTP, dGTP, Boehringer, Germany), PCR buffer containing 1.5 mM MgCl 2 (Perkin Elmer, Germany), Taq polymerase 
Gold (Perkin Elmer, Germany) and 1μM of each primer. The material used was overlayered with 50μL mineral oil in each case. Amplification was performed over 34 cycles using a TRIO-
Thermocycler ® (Biometra, Germany), denaturing at 94℃ (first cycle 3 min, all further cycles 30 sec), annealing at 59 ℃ (30 sec) and extension at 70 ℃ (30 sec, in the last cycle 10 min). If 
the PCR was negative in the first run a second PCR-run has been performed. Detection of amplificates: Amplification products were visualized by submarine minigel electrophoresis in a 
4% composite gel (Biozym, Germany) stained with ethidium bromide. Subsequent gel evaluation was performed with the aid of Phoretix 1D GelAnalysis Software (SLG, Germany). After 
Southern Blot hybridization with the respective peroxidase-labelled probes, the specificity of the amplification products was confirmed using the ECL ® direct nucleic acid labelling and 
detection system in accordance with the manufacturer’s data (Amersham, Germany). The DNA probes needed for this purpose were obtained by sequential amplification of the respective 
PCR amplificates from L. infantum (100 bp products) with subsequent cleanup (Qiagen, Germany). Possible cross contamination was prevented by the use of aerosol-protected filter tips and 
disposable gloves and strict separation of areas for sample preparation, PCR runs (UV-irradiated laminar flow bench), amplification and gel electrophoresis.” 
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 674 
Table 8 Risk of bias assessment of studies in which PCR was performed at follow-up. 675 
Risk of bias item (Ariti et al., 2013)  
 
(Miro et al., 2009) 
 
(Pennisi et al., 2005),  
 
(Plevraki et al., 2006) 
 
(Saridomichelakis et al., 
2005) 
 
Selection bias 
Was allocation to 
treatment group 
randomized? 
Yes—Low risk Yes—Low risk Yes—Low risk No—High risk Yes—Low risk 
Selection bias 
Does the study describe 
the method to conceal 
allocation? 
No—High risk No—High risk No—High risk No—High risk No—High risk 
Performance bias 
Were measures to blind 
owners/personnel 
described? 
No—Low risk 
Parasitological cure is an 
outcome that should not 
be affected by dog carers’ 
knowledge of treatment 
group. 
No—Low risk 
Parasitological cure is an 
outcome that should not 
be affected by dog carers’ 
knowledge of treatment 
group. 
No—Low risk 
Parasitological cure is an 
outcome that should not 
be affected by dog carers’ 
knowledge of treatment 
group. 
Yes—Low risk Yes—Low risk 
Detection bias 
Do they describe 
measures to blind 
outcome assessors? 
No—Low risk 
PCR is an objective test 
that is unlikely to be 
affected by assessors’ 
knowledge of treatment 
group. 
No—Low risk 
PCR is an objective test 
that is unlikely to be 
affected by assessors’ 
knowledge of treatment 
group. 
No—Low risk 
PCR is an objective test 
that is unlikely to be 
affected by assessors’ 
knowledge of treatment 
group. 
No—Low risk 
PCR is an objective test 
that is unlikely to be 
affected by assessors’ 
knowledge of treatment 
group. 
No—Low risk 
PCR is an objective test 
that is unlikely to be 
affected by assessors’ 
knowledge of treatment 
group. 
Attrition bias 
Were there incomplete 
outcome data in the 
study? 
No loss to follow-up—
Low risk 
Loss to follow-up but 
explained—Low risk 
Losses were minimal and 
balanced between groups. 
Loss to follow-up but 
explained—High risk 
>20% of dogs in the 
control group were lost to 
follow-up. Some 
withdrawals were related 
to treatment. A sensitivity 
Loss to follow-up but 
explained—Unclear risk 
There were few losses but 
the initial sample size was 
very low and the losses 
were differential between 
groups. 
Loss to follow-up but 
explained—Unclear risk 
>20% of dogs lost in 
some groups; losses 
differential between 
groups and some may 
have been related to 
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Risk of bias item (Ariti et al., 2013)  
 
(Miro et al., 2009) 
 
(Pennisi et al., 2005),  
 
(Plevraki et al., 2006) 
 
(Saridomichelakis et al., 
2005) 
 
analysis was not done to 
determine potential 
impact of losses. 
treatment. 
Reporting bias 
Was there selective 
reporting of outcomes? 
Yes—Unclear risk 
The data collected at day 
360 of follow-up were not 
reported. 
Yes—High risk 
The parasitological cure 
rate for individual dogs 
was not reported or 
summarized despite being 
available. Only reported 
median parasite load. 
No—Low risk Yes—High risk 
The descriptive data for 
parasite load were not 
reported, only the p-
values for the difference 
in loads between start and 
end of treatment were 
reported in groups in 
which the change was 
significant. 
No—Low risk 
Other bias 
Was the sensitivity of the 
assay(s) used at follow-up 
reported? 
No—Low risk 
PCR is understood to be a 
relatively sensitive test for 
Leishmania. 
No—Low risk 
PCR is understood to be a 
relatively sensitive test for 
Leishmania. 
No—Low risk 
PCR is understood to be a 
relatively sensitive test for 
Leishmania. 
No—Low risk 
PCR is understood to be a 
relatively sensitive test for 
Leishmania. 
No—Low risk 
PCR is understood to be a 
relatively sensitive test for 
Leishmania. 
Other bias 
Was funding source 
reported? Were conflicts 
of interest disclosed? 
Were confounders 
adequately accounted for 
through randomization, 
etc.? Could reinfection 
occur during follow-up 
differentially between 
groups? Other sources of 
bias? 
—Unclear risk 
Funding/conflict of 
interest: not reported 
Confounding: randomized 
Reinfection: may have 
occurred and potential for 
reinfection was 
differential between 
groups. 
The number of treatment 
courses was dependent on 
the performance of dog. 
Some dogs received 
treatment for the entire 
—Unclear risk 
Funding by the 
pharmaceutical company 
making one of the 
interventions 
Conflict of interest: not 
reported 
Confounding: randomized 
Reinfection: deltamethrin-
impregnated collars used 
to prevent reinfection 
—Unclear risk 
Funding/conflict of 
interest: not reported 
Confounding: randomized 
Reinfection: possible but 
not differential between 
groups 
—High risk 
Funding/conflict of 
interest: not reported 
Confounding: not 
randomized and health 
status varied between 
groups.  
Reinfection: potential for 
reinfection differential 
between groups (some 
intervention dogs kept by 
owners and all placebo 
dogs kept at veterinary 
hospital) 
—Unclear risk 
Funding: not an issue 
Conflict of interest: not 
reported 
Confounding: randomized 
and health status did not 
vary between groups 
Reinfection: possible but 
not differential between 
groups  
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Risk of bias item (Ariti et al., 2013)  
 
(Miro et al., 2009) 
 
(Pennisi et al., 2005),  
 
(Plevraki et al., 2006) 
 
(Saridomichelakis et al., 
2005) 
 
follow-up and some 
didn’t in the same group. 
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Table 9 Risk of bias assessment of studies in which xenodiagnosis was performed at follow-up. 678 
Risk of bias domain (Guarga et al., 2002) 
 
(Miro et al., 2011) 
 
Selection bias 
Was allocation to treatment group randomized? 
Not reported—High risk Not reported—High risk 
Selection bias 
Does the study describe the method to conceal 
allocation? 
No—High risk No—High risk 
Performance bias 
Were measures to blind owners/personnel described? 
No—Low risk 
Parasitological cure is an outcome that should not be 
affected by dog carers’ knowledge of treatment group. 
No—Low risk 
Parasitological cure is an outcome that should not be 
affected by dog carers’ knowledge of treatment group. 
Detection bias 
Do they describe measures to blind outcome assessors? 
No—High risk 
Test protocol somewhat subjective and assessor’s 
knowledge of treatment group could have influenced 
time spent looking for parasites. 
No—High risk 
Test protocol somewhat subjective and assessor’s 
knowledge of treatment group could have influenced 
time spent looking for parasites. 
Attrition bias 
Were there incomplete outcome data in the study? 
No loss to follow-up—Low risk Loss to follow-up but explained—High risk 
Almost 50% of dogs in one group lost to follow-up. 
Losses differential between groups. Some reasons for 
losses were related to treatment (e.g., treatment failure 
and death). No sensitivity analysis performed. 
Reporting bias 
Was there selective reporting of outcomes? 
Yes—High risk 
The infectivity of individual dogs was not reported or 
summarized despite being available. Only the overall 
infectivity of the group was reported. 
No—Low risk 
Other bias 
Was the sensitivity of the assay(s) used at follow-up 
reported? 
No—Unclear risk 
Without knowledge of the sensitivity of the 
xenodiagnosis technique, we can’t tell if results are 
biased. 
No—Unclear risk 
Without knowledge of the sensitivity of the 
xenodiagnosis technique, we can’t tell if results are 
biased. 
Other bias 
Was funding source reported? Were conflicts of 
interest disclosed? Were confounders adequately 
accounted for through randomization, etc.? Could 
reinfection occur during follow-up differentially 
—Unclear risk 
Funding/conflict of interest: not reported 
Confounding: unsure if randomized and health status 
of dogs unclear 
Reinfection: possible but unsure if bias occurred 
—Unclear risk 
Funding: Bayer, but unsure if this company has an 
interest in Leishmania treatment 
Conflict of interest: not reported 
Confounders: unsure if randomized but some potential 
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Risk of bias domain (Guarga et al., 2002) 
 
(Miro et al., 2011) 
 
between groups? Other sources of bias? (placebo group was untreated throughout follow-up, 
whereas treatment group was only off treatment for 
part of the follow-up period) 
confounders evenly distributed between groups 
Reinfection: possible and potential was differential 
between groups 
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 680 
Table 10 Risk of bias assessment of studies in which parasite load quantification was performed at follow-up. 681 
Risk of bias domain (Miro et al., 2009) 
 
(Neogy et al., 1994) 
 
(Oliva et al., 1998) 
 
(Plevraki et al., 2006) 
Selection bias 
Was allocation to treatment 
group randomized? 
Yes—Low risk Yes—Low risk Yes—Low risk No—High risk 
Selection bias 
Does the study describe the 
method to conceal allocation? 
No—High risk No—High risk No—High risk No—High risk 
Performance bias 
Were measures to blind 
owners/personnel described? 
No—Low risk 
Parasite load is an outcome that 
should not be affected by dog 
carers’ knowledge of treatment 
group. 
No—Low risk 
Parasite load is an outcome that 
should not be affected by dog 
carers’ knowledge of treatment 
group. 
No—Low risk 
Parasite load is an outcome that 
should not be affected by dog 
carers’ knowledge of treatment 
group. 
Yes—Low risk 
Detection bias 
Do they describe measures to 
blind outcome assessors? 
No—Low risk 
PCR parasite load 
quantification is an objective 
test that is unlikely to be 
affected by assessors’ 
knowledge of treatment group. 
No—High risk 
Cytological parasite load 
quantification is subjective and 
assessors’ knowledge of 
treatment group may have 
affected time spent looking for 
parasites. 
No—High risk 
Cytological parasite load 
quantification is subjective and 
assessors’ knowledge of 
treatment group may have 
affected time spent looking for 
parasites. 
No—High risk 
Cytological parasite load 
quantification is subjective and 
assessors’ knowledge of 
treatment group may have 
affected time spent looking for 
parasites.  
Attrition bias 
Were there incomplete outcome 
data in the study? 
Loss to follow-up but 
explained—Low risk 
Losses were minimal and 
balanced between groups. 
No loss to follow-up—Low risk No loss to follow-up—Low risk Loss to follow-up but 
explained—Unclear risk 
There were few losses but the 
initial sample size was very low 
and the losses were differential 
between groups. 
Reporting bias 
Was there selective reporting of 
outcomes? 
Yes—High risk 
The parasitological cure rate for 
individual dogs was not 
reported or summarized despite 
No—Low risk No—Low risk Yes—High risk 
The descriptive data for parasite 
load were not reported, only the 
p-values for the difference in 
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Risk of bias domain (Miro et al., 2009) 
 
(Neogy et al., 1994) 
 
(Oliva et al., 1998) 
 
(Plevraki et al., 2006) 
being available. Only reported 
median parasite load. 
loads between start and end of 
treatment were reported in 
groups in which the change was 
significant. 
Other bias 
Was the sensitivity of the 
assay(s) used at follow-up 
reported? 
No—Unclear risk 
PCR is understood to be a 
relatively sensitive test for 
detecting Leishmania; however, 
it is unclear whether it is 
accurate or precise to measure 
parasite load. 
No—High risk 
Cytological methods are known 
to be potentially affected by 
measurement error and 
sampling error, reducing 
accuracy and precision. 
No—High risk 
Cytological methods are known 
to be potentially affected by 
measurement error and 
sampling error, reducing 
accuracy and precision. 
No—High risk 
 
Other bias 
Was funding source reported? 
Were conflicts of interest 
disclosed? Were confounders 
adequately accounted for 
through randomization, etc.? 
Could reinfection occur during 
follow-up differentially 
between groups? Other sources 
of bias? 
—Unclear risk 
Funding by the pharmaceutical 
company making one of the 
interventions 
Conflict of interest: not 
reported 
Confounding: randomized 
Reinfection: deltamethrin-
impregnated collars used to 
prevent reinfection 
—Unclear risk 
Funding/conflict of interest: not 
reported 
Confounding: randomized, 
unsure if potential confounders 
evenly distributed 
Reinfection: dogs kept in 
kennel with no description of 
efforts to prevent reinfection 
—Unclear risk 
Funding/conflict of interest: not 
reported 
Confounding: randomized, 
unsure if potential confounders 
evenly distributed 
Reinfection: possible due to 
long follow-up, no preventive 
efforts described 
—High risk 
Funding/conflict of interest: not 
reported 
Confounding: not randomized 
and health status varied 
between groups.  
Reinfection: potential for 
reinfection differential between 
groups (some intervention dogs 
kept by owners and all placebo 
dogs kept at veterinary hospital) 
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Table 11 Risk of bias assessment of longitudinal case series and studies with poor quality reporting.  684 
Risk of bias domain (Moritz et al., 1998) 
 
(Slappendel and Teske, 1997),  
 
(Steuber et al., 1998) 
 
Selection bias 
Was allocation to treatment group 
randomized? 
No—High risk Yes—Low risk No—High risk 
Selection bias 
Does the study describe the method to 
conceal allocation? 
No—High risk No—High risk No—High risk 
Performance bias 
Were measures to blind 
owners/personnel described? 
No—Low risk 
Outcome of interest unlikely to have 
been influenced by dog carers’ 
knowledge of treatment group. 
No—Low risk 
Outcome of interest unlikely to have 
been influenced by dog carers’ 
knowledge of treatment group. 
No—Low risk 
Outcome of interest unlikely to have 
been influenced by dog carers’ 
knowledge of treatment group. 
Detection bias 
Do they describe measures to blind 
outcome assessors? 
No—Low risk 
PCR is an objective test that is unlikely 
to be affected by assessors’ knowledge 
of treatment group. 
No—High risk 
Microscopy is subjective and assessors’ 
knowledge of treatment group may have 
affected time spent looking for parasites. 
No—Low risk 
PCR is an objective test that is unlikely 
to be affected by assessors’ knowledge 
of treatment group. 
Attrition bias 
Were there incomplete outcome data in 
the study? 
Loss to follow-up not explained—Low 
risk 
Only one dog was lost to follow-up. 
Loss to follow-up not explained—High 
risk 
Losses occurred immediately after 
treatment began that were not included 
in the results. Losses later in study may 
have been treatment-related and 
differential between groups. 
Loss to follow-up not explained—High 
risk 
Most dogs did not complete the 
maximum follow-up as follow-up was 
based on response to treatment. Some 
dogs didn’t complete one treatment 
course. Losses were differential between 
groups. 
Reporting bias 
Was there selective reporting of 
outcomes? 
Yes—High risk 
Some outcome data were missing and 
PCR results not reported sufficiently. 
Yes—High risk 
Data not provided for the numbers of 
dogs receiving multiple courses of 
treatment or cross-over treatments. 
Multiple treatments would influence the 
long-term outcomes. Data on dogs 
remaining positive after 365 days not 
reported (only relapses reported).  
Yes—High risk 
Complete data not properly reported or 
summarized at different points of 
follow-up. Without knowing the full 
details of how the individual dogs were 
treated and followed, it is impossible to 
obtain valid inferences from the results 
provided. 
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Risk of bias domain (Moritz et al., 1998) 
 
(Slappendel and Teske, 1997),  
 
(Steuber et al., 1998) 
 
Other bias 
Was the sensitivity of the assay(s) used 
at follow-up reported? 
No—Low risk 
PCR is understood to be a relatively 
sensitive test for Leishmania. 
No—High risk 
Microscopy is not highly sensitive due 
to potential sampling error and 
measurement error. The microscopy 
protocol was not strict. 
No—Low risk 
PCR is understood to be a relatively 
sensitive test for Leishmania. 
Other bias 
Was funding source reported? Were 
conflicts of interest disclosed? Were 
confounders adequately accounted for 
through randomization, etc.? Could 
reinfection occur during follow-up 
differentially between groups? Other 
sources of bias? 
—High risk 
Funding/conflict of interest: not reported 
Confounding: not randomized, no 
information on potential confounders 
Reinfection: Unclear 
Other: Treatment protocol changed 
according to the performance of the dog. 
If dog did not respond to treatment, 
another treatment course was added. 
Outcome at the end of follow-up would 
have been biased by number of 
treatment courses. 
—High risk 
Funding: Rhone Merieux provided the 
intervention 
Conflict of interest: not reported 
Confounding: Differential loss to 
follow-up may have caused potential 
confounders to be differentially 
distributed between groups. 
Reinfection: possibility low (inclusion 
criteria was that owner would not bring 
dog to a Leishmania-endemic area) 
Other: Study protocol was not strict and 
dogs were allowed to receive multiple 
treatments and cross-over between 
groups 
—Unclear risk 
Funding/conflict of interest: not reported 
Confounding: not randomized, potential 
confounders may not have been equally 
distributed between groups 
Reinfection: not possible (dogs never off 
treatment before end of follow-up) 
Other: Treatment protocol changed 
according to the performance of the dog. 
If dog did not respond to treatment, 
another treatment course was added. 
Outcome at the end of follow-up would 
have been biased by number of 
treatment courses. 
Paradies (2012) was not assessed as it was an observational study and could not be evaluated with a tool designed to assess the quality of randomized controlled trials. 685 
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Table 12 Relevant results reported in 5 included studies in which PCR was performed at follow-up.  687 
                                                     
8 At least one bias domain with “High” or “Unclear” risk of bias. (NR = Not reported and excluded from meta-analysis) 
Author Treatment 
protocol 
Duration of 
follow-up 
(days) 
Time not on 
treatment (days) 
Dogs 
enrolled 
Dogs 
completed 
treatment 
Dogs 
completed 
follow-up 
Dogs PCR 
negative at 
follow-up 
PCR samples High or unclear 
risk of bias in 
results?
8
 
(Ariti et 
al., 
2013) 
Allopurinol: 
10mg/kg PO 
BID x 360 days 
Miltefosine: 2 
mg/kg PO SID 
x 30 days 
360 for some 
dogs and 720 
for others 
0 for some dogs 
and 360 for 
others 
14 14 14 0 Blood, 
conjunctiva, 
lymph node 
Yes 
(Ariti et 
al., 
2013) 
Difloxacin: 5 
mg/kg PO x 30 
days 
Metronidazole: 
25 mg/kg PO x 
30 days 
720 660 for some 
dogs and 690 for 
others 
13 13 13 3 Blood, 
conjunctiva, 
lymph node 
Yes 
(Ariti et 
al., 
2013) 
Meglumine 
antimoniate: 
100 mg/kg SQ 
BID x 30 days 
Allopurinol: 10 
mg/kg PO BID 
x 365 days 
720 0 for some dogs 
and 360 for 
others 
15 15 15 5 Blood, 
conjunctiva, 
lymph node 
Yes 
(Miro et 
al., 
2009) 
Allopurinol: 10 
mg/kg PO BID 
x 196 days 
Miltefosine: 2 
mg/kg PO SID 
x 28 days 
196 0 37 33 33 NR Bone marrow Yes 
(Miro et 
al., 
Meglumine 
antimoniate: 50 
196 0 36 32 32 NR Bone marrow  Yes 
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9 Three dogs were PCR negative at some point during follow-up, but all were positive at the end of follow-up. 
10 Four dogs were PCR negative at some point during follow-up. Two of these became PCR positive at the end of follow-up. The two PCR-negative dogs at the end of follow-up had been PCR 
positive 30 and 60 days before. 
11
  Plevraki et al., 2006, these 5 groups were based on the results of urinalysis (protein concentration) and SCr  
 
2009) mg/kg SQ BID 
x 196 days 
Allopurinol: 10 
mg/kg PO BID 
x 196 days 
(Pennisi 
et al., 
2005) 
Metronidazole: 
25 mg/kg PO 
SID x 90 days 
Spiramycin: 
150,000 IU/kg 
PO SID x 90 
days 
210 120 13 12 9 0
9
 Blood, bone 
marrow, lymph 
node 
Yes 
(Pennisi 
et al., 
2005) 
Meglumine 
antimoniate: 55-
100 mg/kg SQ 
BID x 90 days 
Allopurinol: 20 
mg/kg PO BID 
x 90 days 
210 120 14 10 8 2
10
 Blood, bone 
marrow, lymph 
node 
 Yes 
(Plevraki 
et al., 
2006)
11
 
 
Allopurinol: 10 
mg/kg PO BID 
x 180 days 
180 0 12 12 12 0 Bone marrow Yes 
(Plevraki 
et al., 
2006) 
Allopurinol: 10 
mg/kg PO BID 
x 180 days 
180 0 10 10 10 0 Bone marrow Yes 
(Plevraki 
et al., 
Allopurinol: 10 
mg/kg PO BID 
180 0 8 7 7 0 Bone marrow Yes 
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 689 
  690 
2006) x 180 days 
(Plevraki 
et al., 
2006) 
—— 180 0 5 5 5 0 Bone marrow Yes 
(Plevraki 
et al., 
2006) 
—— 180 0 5 4 4 0 Bone marrow Yes 
(Saridom
ichelakis 
et al., 
2005) 
20 mg/kg PO 
SID x 7 days at 
the beginning of 
each month for 
8 months 
365 125 25 19 19 1 Bone marrow Yes 
(Saridom
ichelakis 
et al., 
2005) 
—— 365 125 23 16 16 2 Bone marrow Yes 
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 691 
Table 13 Relevant results reported in 2 included studies in which xenodiagnosis was performed at follow-up. (NR = Not reported) 692 
 693 
 694 
 695 
 696 
                                                     
12 At least one bias domain with “High” or “Unclear” risk of bias. 
Author Treatment protocol Duration of 
follow-up 
(days) 
Time not on 
treatment 
(days) 
Dogs 
enrolled 
Dogs 
completed 
treatment 
Dogs 
completed 
follow-up 
Dogs 
negative at 
follow-up 
High or unclear 
risk of bias in 
results?
12
 
(Guarga et 
al., 2002) 
Meglumine antimoniate: 100 mg/kg 
SQ SID x 21 days 
Antigenic preparation: 300 µl 
beginning 7 days before start of 
antimonial therapy and repeated at 
intervals of 14 days for 3 treatments 
180 159 5 5 5 NR Yes 
(Guarga et 
al., 2002) 
N/A 180 180 5 5 5 NR Yes 
(Miro et 
al., 2011) 
Meglumine antimoniate: 35 mg/kg SQ 
BID x 28 days 
Allopurinol: 10 mg/kg PO BID x 180 
days 
180 0 12 12 12 12  Yes 
(Miro et 
al., 2011) 
Meglumine antimoniate 35 mg/kg SQ 
BID x 28 days 
180  152 11 9 9 8 Yes 
(Miro et 
al., 2011) 
Allopurinol  10 mg/kg PO BID x 180 
days 
180 0 9 5 5 5 Yes 
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 697 
Table 14 Relevant results reported in 4 included studies in which parasite load was estimated before treatment and at follow-up. (NR = Not reported, IQR = 698 
interquartile range, SD = standard deviation) 699 
                                                     
13 At least one bias domain with “High” or “Unclear” risk of bias. 
Author Treatment 
protocol 
Duration 
of follow-
up (days) 
Time not 
on 
treatment 
(days) 
Dogs 
enrolled 
Dogs 
completed 
treatment 
Dogs 
completed 
follow-up 
Dogs 
negative at 
follow-up 
Test & 
Sample 
type 
Parasite load High or 
unclear risk 
of bias in 
results?
13
 
(Miro 
et al., 
2009) 
Allopurinol: 10 
mg/kg PO BID x 
196 days 
Miltefosine: 2 
mg/kg PO SID x 
28 days 
196 0 37 33 33 NR PCR Bone 
marrow 
Median (IQR) 
parasites/ml 
Pre-treatment: 2312.5 
(6.25–27500) (n = 
36) 
Post-treatment: 0 (0-
929.25) (n = 33) 
Yes 
(Miro 
et al., 
2009) 
Meglumine 
antimoniate: 50 
mg/kg SQ BID x 
196 days 
Allopurinol: 10 
mg/kg PO BID x 
196 days 
196 0 36 32 32 NR PCR Bone 
marrow 
Median (IQR) 
parasites/ml 
Pre-treatment: 998 
(<25–12025) (n = 36) 
Post-treatment: 0 (0–
<25) (n = 32) 
 Yes 
(Plevra
ki et al., 
2006) 
Allopurinol: 10 
mg/kg PO BID x 
180 days 
180 0 12 12 12 0 PCR Bone 
marrow 
Significant difference 
between pre- and 
post-treatment (p = 
0.0156) 
Yes 
(Plevra
ki et al., 
2006) 
Allopurinol: 10 
mg/kg PO BID x 
180 days 
180 0 10 10 10 0 PCR: Bone 
marrow 
No significant 
difference between 
pre- and post-
treatment parasitic 
Yes 
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loads. 
(Plevra
ki et al., 
2006) 
Allopurinol: 10 
mg/kg PO BID x 
180 days 
180 0 8 7 7 0 PCR Bone 
marrow 
Significant difference 
between pre- and 
post-treatment 
parasite loads (p = 
0.0156) 
Yes 
(Plevra
ki et al., 
2006) 
—— 180 0 5 5 5 0 PCR Bone 
marrow 
No significant 
difference between 
pre- and post-
treatment parasitic 
loads. 
Yes 
(Plevra
ki et al., 
2006) 
—— 180 0 5 4 4 0 PCR Bone 
marrow 
No significant 
difference between 
pre- and post-
treatment parasitic 
loads. 
Yes 
(Neogy 
et al., 
1994) 
N-
methylglucamin
eantimonate 
300 mg/kg IM 
q48h x 40 days 
180 140 8 8 8 3 Cytology 
Bone 
marrow 
Pre-treatment: 8 dogs 
had 1–10 
amastigotes/  1 oil 
immersion field 
(x100)  
Post-treatment: 5 
dogs had 1–10 
amastigotes/ 100 oil 
immersion fields 
(x100) and 3 dogs 
had no amastigotes 
Yes 
(Neogy 
et al., 
1994) 
Partially 
purified 
antigenic 
Fraction 2, 
derived from L. 
infantum 
180 159 8 8 8 2 Cytology 
Bone 
marrow 
Pre-treatment: 8 dogs 
had 1–10 
amastigotes/  1 oil 
immersion field 
(x100)  
Post-treatment: 6 
dogs had 1–10 
Yes 
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14 Parasite density score: 0 (no parasites/1000 micro fields) to 6 (>100 parasites/micro field) (Chulay and Bryson) 
promastigotes 
50 µg IM q7d x 
21 days 
amastigotes/ 100 oil 
immersion fields 
(x100) and 2 dogs 
had no amastigotes 
(Neogy 
et al., 
1994) 
Meglumine 
antimoniate: 300 
mg/kg IM q48h x 
40 days 
Fraction 2: 50 µg 
IM q7d x 21 days, 
started 15 days 
after antimonial 
treatment 
completed  
180 104 8 8 8 8 Cytology  
Bone 
marrow 
Pre-treatment: 8 dogs 
had 1–10 
amastigotes/  1 oil 
immersion field 
(x100)  
Post-treatment: 0 
dogs had any 
amastigotes in any oil 
immersion field 
Yes 
(Oliva 
et al., 
1998) 
Aminosidine 
sulphate  3.5 mg 
base/kg SQ BID x 
21 days 
180 159 11 11 11 2 Cytology 
Bone 
marrow, 
lymph node 
Mean (SD) parasite 
density score
14
 
Pre-treatment: Bone 
marrow = 1.4 (0.7); 
Lymph node = 1.0 
(0.8)       (n = 11) 
Post-treatment: Bone 
marrow = 0.9 (0.3); 
Lymph node = 0.9 
(0.3)       (n = 11) 
Yes 
(Oliva 
et al., 
1998) 
meglumine 
antimoniate  30 
mg Sb/kg IM SID 
x 21 days 
180 159 10 10 10 4 Cytology 
Bone 
marrow, 
lymph node 
Mean (SD) parasite 
density score
14
 
Pre-treatment: Bone 
marrow = 1.2 (0.8); 
Lymph node = 1.3 
(0.7)       (n = 10) 
Post-treatment: Bone 
marrow = 0.7 (0.7); 
Yes 
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 700 
 701 
 702 
 703 
  704 
Lymph node = 0.8 
(0.9)       (n = 10) 
(Oliva 
et al., 
1998) 
Meglumine 
antimoniate: 20 
mg Sb/kg IM SID 
x 21 days 
Aminosidine: 3.5 
mg base/kg SQ 
BID x 21 days 
180 159 11 11 11 5 Cytology 
Bone 
marrow, 
lymph node 
Mean (SD) parasite 
density score
14
 
Pre-treatment: Bone 
marrow = 1.1 (0.7); 
Lymph node = 1.5 
(1.0) (n =11) 
Post-treatment: Bone 
marrow = 0.7 (0.8); 
Lymph node = 0.6 
(0.7) (n = 11) 
Yes 
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Table 15 Data extractable from longitudinal case series and studies with poor quality reporting. (NR = Not reported) 705 
Author Treatment 
protocol 
Duration 
of follow-
up (days) 
Time  not 
on 
treatment 
(days) 
Dogs 
enrolled 
Dogs 
completed 
treatment 
Dogs 
completed 
follow-up 
Dogs 
negative at 
follow-up 
PCR 
samples 
Parasite 
load 
At least one domain 
with “High” or 
“Unclear” risk of 
bias? 
(Moritz et 
al., 1998) 
Meglumine 
antimoniate:  50 
mg/kg x 2 days, 
then 100 mg/kg x 
8 days, then 14 
days off, then 
repeat course of 
treatment 
780–1440 746–1404 6 5 PCR: 
Unclear 
PCR: 
Unclear 
Blood, 
bone 
marrow 
Not done Yes 
(Moritz et 
al., 1998) 
Meglumine 
antimoniate: 50 
mg/kg x 2 days, 
then 100 mg/kg x 
8 days, then 14 
days off, then 
repeat course of 
treatment 
Allopurinol:10 
mg/kg PO BID x 
21–35–630 days  
270–1440 Unclear 7 7 PCR: 7 PCR: 2 Blood, 
bone 
marrow 
Not done Yes 
(Moritz et 
al., 1998) 
Allopurinol:10 
mg/kg PO BID x 
? days 
270–480 Unclear 3 3 PCR: 3 PCR: 2 Blood, 
bone 
marrow 
Not done Yes 
(Paradies 
et al., 
Meglumine 
antimoniate: 50 
365 245-337 6 6 See 
footnote
15
 
NR N/A Not done Yes 
                                                     
15 "Very few cases" in this group had lymph node cytology done during follow-up. All that had cytology were positive. Outcome was clinico-pathological relapse = return of abnormal laboratory 
parameters as well as RBC mass (Hct <35%; reference interval 35–50%), hyperproteinemia (serum total protein, TP >7.5 g/dL; reference interval 5.5–7.5 g/dL), abnormalities of 
albumin/globulin ratio (A/G <0.6; reference interval 0.7–1.3). Separately, cytology on lymph node samples was performed whenever possible. 
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2012) mg/kg SQ BID 
until clinical 
recover (60-120 
days for the dogs 
in the trial) 
(Paradies 
et al., 
2012) 
Meglumine 
antimoniate: 50 
mg/kg SQ BID x 
56 days or until 
clinico-
pathological 
recovery 
Allopurinol: 15 
mg/kg PO BID x 
180 days, begun 
after antimonial 
discontinued 
365 129 or less 6 6 See 
footnote
16
 
NR N/A Not done Yes 
(Paradies 
et al., 
2012) 
allopurinol 15 
mg/kg PO BID x 
365 days 
365 0 6 6 See 
footnote
17
 
NR N/A Not done Yes 
Slappendel 
(Slappend
el and 
See footnote
18
 365 or 730 
or for as 
long as 
Unclear 22 20 Unclear See 
footnote
19
 
N/A Not done Yes 
                                                     
16 "The low number of available lymph node cytology tests [in this group] resulted negative in all dogs." 
17 "Most of the lymph node cytology resulted positive throughout the study in this group." 
18 Dose: 100 mg/kg IV SID x 21 days; "In case of partial remission (PR) or no response (NR), the same treatment was given for another 3 weeks ('prolonged treatment'). If there was a relapse, 
therapy was resumed but was changed from IV to SC administration or vice versa (cross-over therapy) and evaluated again 3 weeks later." 
19 "Three weeks after the first treatment for 21 days, the overall clinical condition had improved significantly in most dogs in both groups and the cytological examination for parasites was 
negative in 24 (70.6%) of 34 previously positive dogs. Three weeks after either a normal or a prolonged course of treatment was completed, remission was obtained in 85.4% of 41 patients 
(partial remission in 3 cases and complete remission in 32). Parasites could be detected in only 2 (5.8%) of 34 initially positive dogs, while no significant difference (P=0.487) between the 
groups was noted. In addition, mean PCV had increased and proteinuria had decreased in both groups significantly. No significant difference (P=0.671), however, was observed between the 
groups. Response rates in both groups were not significantly different (P=0.663).” 
Within 1 year, relapses had occurred in 15 of 18 dogs in group A and in 11 of 17 dogs in group B (P=0.264). No significant difference (P=0.412) was observed in relapse free-period between 
group A dogs and group B dogs" 
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Teske, 
1997) 
possible 
(Slappend
el and 
Teske, 
1997) 
See footnote
20
 365 or 730 
or for as 
long as 
possible 
Unclear 22 21 Unclear See 
footnote
19
 
N/A Not done Yes 
(Steuber et 
al., 1998) 
50 mg/kg IM 
days 1&2, 
followed by 100 
mg/kg IM days 3-
10. If further 
treatment courses 
were required, an 
interval of 10-14 
days was left 
between courses. 
Unclear Unclear Unclear Unclear
21
 PCR: 
Unclear 
PCR: 
Unclear 
Blood, 
bone 
marrow 
Not done Yes 
(Steuber et 
al., 1998) 
Pretreated with 
Glucantime 
(protocol not 
reported); 
Allopurinol 10 
mg/kg PO BID x 
21 days, 35 days, 
180 days, or 600 
days 
35, 180, or 
600 
Unclear—
likely 0 
(dogs tested 
immediatel
y after 
treatment) 
3 3 PCR: 3 PCR: 2 Blood, 
bone 
marrow 
Not done Yes 
(Steuber et 
al., 1998) 
Allopurinol 10 
mg/kg PO BID x 
21-35 days 
21–35 Unclear—
likely 0 
(dogs tested 
immediatel
Unclear 7 PCR: 7 PCR: 2 Blood, 
bone 
marrow 
Not done  Yes 
                                                     
20 Dose: 100 mg/kg SQ SID x 21 days; "In case of partial remission (PR) or no response (NR), the same treatment was given for another 3 weeks ('prolonged treatment'). If there was a relapse, 
therapy was resumed but was changed from IV to SC administration or vice versa (cross-over therapy) and evaluated again 3 weeks later." 
21 Some dogs completed 1 to >3 treatment courses; as well, there were unexplained losses between treatment courses. The number of dogs still positive after treatment course 1 did not equal the 
number of dogs followed in treatment course 2. 
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y after 
treatment) 
FIGURES 706 
Figure 1 Search strategy to identify studies reporting on canine leishmaniosis in Science Citation Index (Web of Knowledge, Thompson Reuters)  707 
# 7 #3 NOT #6 708 
# 6 #4 NOT #5 709 
# 5 AD=(Albania* OR Andorra* OR Armenia* OR Austria* OR Azerbaija* OR Belarus* OR Belgium* OR Bosnia* OR Bulgaria* OR Croatian* OR Cyprus* OR 710 
Cypriot* OR Czech* OR Denmark* OR “Danish” OR Estonia* OR Finland* OR “Finns” OR “Finnish” OR Macedonia* OR France* OR “French” OR Georgia* OR 711 
German* OR Greece* OR Greek* OR Hungary* OR Hungarian* OR Iceland* OR Ireland* OR “Irish” OR Italy* OR Italian* OR Israel* OR Kazakhstan* OR Kyrgyzstan* 712 
OR Latvia* OR Liechtenstein* OR Lithuania* OR Luxemburg* OR Luxembourger* OR Malta* OR Moldavia* OR Montenegro* OR Netherlands OR Holland* OR “Dutch” 713 
OR Norway* OR Norwegian* OR Poland* OR “Polish” OR Portugal* OR “Portuguese” OR Romania* OR Russia* OR “San Marin*” OR Serbia* OR Slovakia* OR 714 
Slovenia* OR Spain* OR Sweden* OR “Swedish” OR “Swiss” OR Switzerland* OR Tajikistan* OR Turkey* OR “Turkish” OR Turkmenistan* OR Ukrain* OR “United 715 
Kingdom*” OR “UK” OR Britain* OR “British” OR England* OR “English” OR Wales* OR “Welsh” OR Scotland* OR “Scottish” OR Uzbekistan* OR “USSR” OR 716 
“Soviet”) 717 
# 4 AD=("united states" OR america* OR "USA" OR "US" OR "canada" OR canadian* OR "mexico" OR mexican* OR brazil* OR colombia* OR argentin* OR peru 718 
OR "peruvian" OR venezuela* OR chile* OR ecuador* OR bolivia* OR paragua* OR urugua* OR guyana* OR suriname* OR guiana* OR "cuba" OR "cuban" OR 719 
guatemala* OR "haiti" OR "haitian" OR bolivia* OR dominican* OR hondura* OR "el salvador*" OR nicaragua* OR "costa rica*" OR "puerto ric*" OR panama* OR 720 
ethiopia* OR sudan* or kenya* OR africa* OR australia*)3  721 
# 3 #2 AND #1 722 
# 2 TS=("canine" OR "canines" OR "dog" OR "dogs" OR "lupus familiaris" OR "l familiaris" OR canidae* OR "canid" OR "canids") 723 
# 1 TS=("leishmaniosis" OR "leishmaniasis" OR "leishmania" OR "l infantum") 724 
 725 
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 726 
Figure 2 Flow diagram showing study identification process for Objective 1-- the review of 727 
diagnostic test evaluations in naïve dogs  728 
 729 
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Records identified through 
database searching 
(n = 7405) 
Additional records identified 
through other sources 
(n = 0) 
Records after duplicates removed 
(n = 3865) 
Records after books, theses, and patents removed 
(n = 3712) 
Records after non-European countries removed 
(n = 3168) 
 
DTE studies included at Level 1 
title/abstract screening 
(n = 234) 
Longitudinal DTE studies 
included at Level 2  
full-text screening 
(n = 7) 
Total records excluded Level 1: n = 2934 
(non-relevant: n = 2870)  
(L. chagasi, mexicana or brasiliensis: n = 64) 
 
Total records excluded Level 2: n = 227 
(not a longitudinal design: n =  216) 
(both PCR and serology not used to ID naïve 
dogs: n = 11) 
 
Studies included in synthesis 
(n =  7) 
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 749 
 750 
Figure 3 Flow diagram showing study identification process  for Objective 2, the review of 751 
treatment outcomes for Canine leishmaniosis 752 
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database searching 
(n = 7405) 
Additional records identified 
through other sources 
(n = 0) 
Records after duplicates removed 
(n = 3865) 
Records after books, theses, and patents removed 
(n = 3712) 
Records after non-European countries removed 
(n = 3168) 
 
Treatment studies included at 
Level 1 title/abstract screening 
(n = 40) 
Treatment studies included at 
Level 2  
full-text screening 
(n = 13) 
Total records excluded Level 1: n = 2934 
(non-relevant: n = 2830)  
(L. chagasi, mexicana or brasiliensis: n = 64) 
 
Total records excluded Level 2: n = 27   
 
 
Studies included in synthesis 
(n =  13) 
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 772 
Figure 4 Forest plot of data about proportion tested with PCR for evidence of Leishmania after extended follow-up periods.  773 
 774 
Studies that did not report data in a manner that could be used to calculate proportion negative are not included (see Table 12 775 
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 930 
A.  DIAGNOSTIC TEST EVALUATION PROTOCOL FOR THE ASSESSMENT OF DIAGNOSTIC TEST 931 
CHARACTERISTICS OF PCR ASSAYS AND SEROLOGICAL ASSAYS (ELISA OR IFAT) TO DETECT 932 
LEISHMANIA INFECTION IN NAÏVE DOGS LONGITUDINAL STUDIES CONDUCTED IN EUROPE SINCE 933 
1990. 934 
1. BACKGROUND AND RATIONALE   935 
The aim of this review is to evaluate the sensitivity and specificity of assays to detect infection of 936 
Leishmania infantum in dogs. Two types of assays are of interest, PCR assays that detect the presence 937 
of the organism (antigen) and the serological assays, ELISA and IFAT that detect the presence of 938 
antibodies.  939 
Canine leishmaniosis (CanL), caused by infection with Leishmania infantum, is a major global vector-940 
borne zoonotic disease potentially fatal to humans and dogs. The latter are the most important natural 941 
reservoir and should therefore be the main target of control measures. Leishmaniosis is known to be 942 
endemic in more than 70 countries in the world, including certain regions of southern Europe. The 943 
movement of infected dogs from endemic regions, together with the potential expansion of sand fly 944 
vector populations in Europe, might represent a risk of introducing the disease into non-endemic 945 
countries.  946 
For that reason, canine leishmaniosis might fall under the category of diseases other than rabies that 947 
require preventive health measures to be adopted by means of a Commission delegated to act in 948 
accordance with the Regulation, in order to ensure protection of those Member States in which an 949 
endemic infection with Leishmania infantum has not been recorded. 950 
To support the Commission in the possible preparation of such an act, the Commission requested 951 
EFSA to assess the available scientific information regarding canine leishmaniosis and to evaluate the 952 
relevance of measures aiming at mitigating the risk of introducing the disease through the movement 953 
of dogs. Testing dogs that move from endemic areas into areas free of Leishmania infantum infections 954 
and treating positive dogs could be possible measures of reducing the risk of introduction into free 955 
areas in the EU 956 
2. Objectives   957 
The objective of this review is to summarize relative sensitivity and specificity estimates reported in 958 
studies of naïve dogs in areas where Leishmania infantum infection is endemic.   959 
3. METHODS   960 
3.1. Criteria for considering studies for this review   961 
3.1.1. Types of studies 962 
Studies that enroll dogs that are naïve for Leishmania infantum infection and live or are introduced to 963 
an endemic region are eligible for the review. The studies must also follow the dogs over time to 964 
detect changes in Leishmania infantum infection status and test for naïvety and infection with 965 
Leishmania infantum using both a PCR assay as a measure of antigen presence and ELISA or IFAT as 966 
measures of serological exposure to Leishmania infantum.   967 
3.1.2. Participants  968 
The target population of interest is naïve dogs at risk of Leishmania infantum in Europe introduced 969 
into or living in endemic regions. Naïve dogs are defined as dogs that test negative for Leishmania 970 
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infantum using both PCR (using any sample) and serology based on ELISA or IFAT. Note that this 971 
definition may be problematic, as studies that use low sensitivity tests as a definition of naïve animals 972 
may not enroll naïve animals. 973 
3.1.3. Index and comparator tests  974 
The aim is to extract sensitivity and specificity data from these studies. The authors may test the 975 
animals with a PCR or serology test of choice during the study and determine the apparent prevalence 976 
of infection. Then the authors may compare the results of the PCR of choice to other assays, other 977 
PCR assays, the same PCR assay on a different tissue or the serological assays ELISA or IFAT. 978 
Therefore, the gold standard will be the authors’ “preferred” PCR and will change between studies. 979 
The comparator test will be that reported by the authors provided it is either a PCR test/tissue or 980 
ELISA or IFAT. Apparent prevalence data will not be extracted. 981 
3.1.4. Target conditions  982 
The target condition of interest is infection with leishmaniosis caused by infection with Leishmania 983 
infantum based on the authors’ preferred PCR assay and test sample.   984 
3.1.5. Search methods for identification of studies   985 
3.1.5.1. Electronic searches  986 
The searches for this review have already been designed and conducted as part of the scoping review. 987 
This approach has been used to make maximum use of the time available for the project. The 988 
following databases were searched: Science Citation Index (SCI), Conference Proceedings Citation 989 
Index – Science (CPCI-S), CAB Abstracts , BIOSIS Citation Index , MEDLINE and MEDLINE In-990 
Process, and Open Grey. These searches will not be updated as the time frame for execution of the 991 
review is limited and the time between the scoping review and the conduct of the review is short.   992 
3.1.6.  Searching other resources 993 
The only additional resource that will be used for the systematic review will be to evaluate if relevant 994 
references are present in the bibliography of papers that are included in the final review. The results of 995 
this additional search will be included in the summary of search provided in the report.  996 
3.1.7. Selection of studies   997 
Based on the prior screening, we identified all studies for which the reviewers responded yes to the 998 
following question:  999 
Question 1: Does the title or abstract describe a primary study in which data may have been collected 1000 
from which diagnostic test characteristics could be calculated for one or more of the following assays 1001 
of interest for canine leishmaniosis: PCR, IFAT, or ELISA? Include only studies evaluating tests in 1002 
dogs (i.e., exclude sand flies, humans, etc.) and exclude studies obviously evaluating L. Mexicana, or 1003 
L. brasiliensi.  1004 
We will now screen these studies to identify studies that meet the more refined eligibility criteria for 1005 
the review question.  1006 
1) Does the abstract describe a study that reports the use of naïve dogs in an endemic region or 1007 
the introduction of naïve dogs into an endemic region? (yes/no) If no. exclude from the 1008 
review.  1009 
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2) Does the abstract or title describe a longitudinal evaluation of infection in an endemic area i.e., 1010 
apparent prevalence of infection or relative sensitivity and specificity may be reported? 1011 
(yes/no)- If no, exclude from the review. 1012 
For studies that pass Q 1 and 2, the full text will be obtained to assess the following question: 1013 
3) Did the study use a testing protocol to assess negative dogs that included both PCR and 1014 
serology (ELISA or IFAT)? (yes/no)- If no, exclude from the review. 1015 
These series of questions will be tested on a test set of abstracts and modified as necessary. When 1016 
agreement between the two independent reviewers is high (kappa > 90%) screening of all abstracts 1017 
will take place. Conflicts will be resolved by discussion.  1018 
3.1.8. Data collection  1019 
After identifying the studies eligible for the review, extraction of study characteristics and results will 1020 
occur and the risk of bias in each study will be assessed. Data collection forms will be developed 1021 
based on the questions below. The forms will be tested on a subset of studies to ensure high agreement 1022 
between reviewers. Data extraction will be performed by one reviewer and verified by the 2
nd
 1023 
reviewer.  Conflicts will be resolved by discussion. This approach is needed because the extraction of 1024 
text makes resolutions of conflicts very time-consuming. Also as we are extracting a number 1025 
comparisons rather than a single pairwise comparison as normally occurs in systematic reviews, it is 1026 
not possible to design automatic conflict resolution forms in DistillerSR® (i.e., we may need to extract 1027 
a comparison of PCR on bone marrow compared to PCR on skin, at 2, 5, and 12 months post-1028 
introduction to the endemic area, and a comparison of PCR on bone marrow compared to ELISA, at 2, 1029 
5, and 12 months post-introduction from the same study). Where ever possible checklists will be used 1030 
or numerical data will be extracted.  1031 
3.1.8.1. Characteristics of the study population to be collected 1032 
1) Country- list of EU member countries and a text box for others options 1033 
2) Year of study conducted (XXXX). If the study doesn’t report the year, this will be scored as 1034 
not reported rather than using the year of publication.  1035 
3) Origin of naïve dog population –local kennel dogs, laboratory dogs, imported from another 1036 
region,  1037 
4) Health status of naïve dog population - clinical (sick) dogs, apparently healthy dogs, mixture, 1038 
not discernible 1039 
5) How was naïvety defined? List all tests conducted (PCR, ELISA, IFAT)  1040 
6) PCR-based method of determining infection- extract exact details of assay (text-based answer) 1041 
7) Tissues used for PCR test- report all used (skin, bone marrow, lymph node, conjunctival, 1042 
other) 1043 
8) What is the cut-off for a positive PCR to assess naïvety? Text (indicate NR if not reported)  1044 
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9) Was this PCR assay also used to test animals for infection later? (yes/no) 1045 
10) ELISA assay used for determination of infection- extract exact details of assay (text-based 1046 
answer – if none, leave blank) 1047 
11) What is the cut-off for a positive ELISA assay used to assess naïvety? Text (indicate NR if not 1048 
reported) 1049 
12) Was this ELISA assay also used to test animals for infection later? (yes/no) 1050 
13) IFAT assay used for determination of infection- extract exact details of assay (text-based 1051 
answer – if none leave blank) 1052 
14) What is the cut-off for a positive IFAT used to assess naïvety? Text (indicate NR if not 1053 
reported) 1054 
15) Was this IFAT assay also used to test animals for infection later? (yes/no) 1055 
16) If you answered no to either 9, 12, or 15 provide details of assays used later.  1056 
3.1.8.2. Relative sensitivity and specificity data extraction (PCR versus PCR) 1057 
1) Referent assay (pick the assay that is used by the authors as a gold standard)-list 1058 
2) Index assay (pick the assay that is used by the authors as a comparator)-list 1059 
3) Number of dogs enrolled in the study 1060 
4) Number of dogs tested using both assays at this time period. 1061 
5) Number of positive dogs based on the referent assay at this time period. 1062 
6) Number of positive dogs based on index test at this time period 1063 
7) Reported sensitivity (express as a proportion)  1064 
8) Measure of precision of sensitivity  (express as SE- back convert CI by dividing by 4)  1065 
9) Reported specificity (express as a proportion)  1066 
10) Measure of precision of specificity  (express as SE- back convert CI by dividing by 4)  1067 
11) Time post-introduction to infection exposure (rounded to nearest month, if 2 weeks use 0.5)  1068 
3.1.8.3. Assessment of methodological quality  1069 
Assessment of methodological quality will be based upon the QUADAS tool domains for diagnostic 1070 
test comparisons (Whiting et al., 2003; Whiting et al., 2006; Whiting et al., 2011).  Consistent with the 1071 
recommendations from the Cochrane Working Group on Diagnostic Test Evaluations Systematic 1072 
Reviews, we will assess the following questions that relate to quality of study execution (even when 1073 
some are eligibility criteria) (Reitsma et al., 2009). Assessment of methodological bias will be 1074 
performed by two reviewers independently and conflicts resolved by discussion.    1075 
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1. Was the spectrum of naïve dogs representative of the dogs who will receive the test in practice? 1076 
(Representative spectrum). The answer to this is likely to be an unclear risk of bias as it is unclear to 1077 
the review team that the candidates for testing are likely to be naïve dogs with short-term exposure to 1078 
infection pressure. The review team suspects that some candidate dogs will also include dogs from 1079 
endemic regions which may have different exposure to other organisms and long-term exposure.  1080 
2.  Is the reference standard likely to classify the target condition correctly? (Acceptable reference 1081 
standard). We will answer yes (low risk of bias) to this question if the reference assay is a bone 1082 
marrow based kDNA assay, otherwise we will assume no and conclude a high risk of bias. 1083 
3.  Is the time period between reference standard and index test short enough to be reasonably sure that 1084 
the target condition did not change between the two tests? (Acceptable delay between tests) If the tests 1085 
are not conducted concurrently we will answer no to this question- i.e., a high risk of bias. 1086 
4.  Did the whole sample or a random selection of the sample receive verification using the intended 1087 
reference standard? (Partial verification avoided) If the study does not test all the dogs (except dead 1088 
dogs) that were originally identified as naïve, we will answer no and assume a high risk of bias.  1089 
5.  Did dogs receive the same reference standard irrespective of the index test result? (Differential 1090 
verification avoided) If the study uses a different reference or index test to test a subset of dogs, we 1091 
will answer no and assume a high risk of bias, i.e. if the study describes only retesting in subsequent 1092 
months animals that test positive (or negative) based on one assay.  1093 
6.  Was the reference standard independent of the index test (i.e. the index test did not form part of the 1094 
reference standard)? (incorporation avoided) If the authors used the index test as part of the reference 1095 
test, we will assign a high risk of bias. 1096 
7.  Were the reference standard results interpreted without knowledge of the results of the index test? 1097 
(index test results blinded)  If the authors do not report blinding of the outcome, we will assess a high 1098 
risk of bias.  1099 
8.  Were the index test results interpreted without knowledge of the results of the reference standard? 1100 
If the authors do not report blinding of the outcome, we will assess a high risk of bias. 1101 
9.  Were the same clinical data available when test results were interpreted as would be available when 1102 
the test is used in practice? If the authors describe having access to clinical data i.e., testing sick dogs, 1103 
then we will assess a high risk of bias, as we assume that candidate dogs will not have clinical signs 1104 
when tested. 1105 
10.  Were uninterpretable/intermediate test results reported? If the authors report discarding 1106 
intermediate test results we will assess a high risk of bias. If the authors do not discuss intermediate 1107 
results we will report an unclear risk of bias. 1108 
11.  Were withdrawals from the study explained? If the authors describe > 10% loss to follow-up, we 1109 
will assign a high risk of bias. If the authors do not report the number of animals that are used in 1110 
sensitivity and specificity we will assign unclear risk of bias, and if all animals are present and 1111 
accounted for, we will assess low risk of bias. Note that death is not a reason for loss-to-follow up, 1112 
rather it is a valid withdrawal.  1113 
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3.1.8.4. Statistical analysis and data synthesis 1114 
As the analysis will to some extent depend upon the type and quantity of data that are located through 1115 
the literature search, it is not possible to fully specify the analysis at the protocol stage. In general 1116 
terms we propose to use a hierarchical random-effects model or a generalized linear model as 1117 
recommended for binary outcome data to model each pairwise comparison (Macaskill et al., 2010). If 1118 
conducted, preliminary analysis and forest plots will be constructed in RevMan. If conducted, 1119 
complicated analyses will be conducted either in SAS using Proc GLIMMIX or R (using one of 1120 
several packages). Given the time available, it may not be possible to use complicated approaches to 1121 
Diagnostic Test Assessment (DTA) analysis such as those described by (Menten et al., 2013). We will 1122 
assess publication bias using previously recommended approaches specific to DTA reviews (Deeks et 1123 
al., 2005; van Enst et al., 2014).  1124 
3.1.8.5. Investigations of heterogeneity  1125 
It will be very difficult to explore sources of heterogeneity using standard approaches, because there is 1126 
no pairwise comparison (Macaskill et al., 2010).  In most systematic reviews of diagnostic tests there 1127 
is a comparison of one assay with another assay. However, in this review, we clearly expect 1128 
heterogeneity because the referent test differs. For example, one study may use a PCR on conjunctiva 1129 
as the referent test and another may use PCR on bone marrow as the referent assay. Further, one study 1130 
may use a 0.6 OD as the ELISA cut-off and another may use a 0.4 OD as the cut-off. Such differences 1131 
clearly explain most of the differences in estimates of sensitivity and specificity. If we do find enough 1132 
studies that have similar pairwise comparisons, we will assess sources of heterogeneity based on naïve 1133 
or introduced dogs.  1134 
3.1.8.6. Sensitivity analyses  1135 
 We will explore the impact of individual studies on a summary effect size if one is reported.  1136 
3.1.8.7. Reporting 1137 
For each study we will provide a table of basic descriptive information. We currently propose to 1138 
organize the presentation of the results by referent assay. This would mean a series of tables of studies 1139 
that use PCR as the referent and compare to other PCR assays using the same tissue. Then we would 1140 
prepare a table for studies that used PCR assays on one tissue as the referent and compared the results 1141 
of the same PCR on a different tissue. We then propose to create tables that compare PCR to ELISA, 1142 
PCR to IFAT, and ELISA to IFAT.  If possible we will include studies at different time periods in the 1143 
same table. If it is sensible and possible, we will create paired forest plots. We do not anticipate 1144 
creating a summary effect size or summary ROC plot.  A risk of bias table will be provided.  1145 
 1146 
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 1148 
 1149 
B.  PROPOSED PROTOCOL FOR REVIEW FOR ASSESSMENT OF PREVALENCE OF  PARASITOLOGICAL 1150 
CURE FOR LEISHMANIOSIS 1151 
1. PI(S) QUESTION (PRISMA ITEM 4) 1152 
 What is the prevalence of parasitological cure (failure to detect organism) after a 12-month 1153 
follow-up period in animals treated with meglumine antimoniate, miltefosine and allopurinol 1154 
or combinations of these drugs for canine leishmaniosis?  1155 
1.1. Eligibility criteria  (PRISMA ITEM 6) 1156 
1.1.1. Relevant participants 1157 
The relevant study population is defined as dogs with confirmed cases of canine leishmaniosis in the 1158 
European region. The European region is defined as member countries of the OIE European region 1159 
(http://www.oie.int/fileadmin/Home/eng/About_us/docs/pdf/2009_Commission_Europe_A.pdf), and 1160 
includes northern Asia (e.g., Russia, Ukraine, Uzbekistan), Turkey, Israel, and several other non-EU 1161 
countries.  The relevant population is treated with any regime that contains meglumine antimoniate, 1162 
miltefosine and allopurinol.  1163 
Types of outcome measures 1164 
The primary outcome of interest is a prevalence of parasitological cure at greater than 12 months after 1165 
the initiation of therapy. This is defined as absence of parasites assessed using an accurate PCR (based 1166 
on other review) or xenodiagnosis after confirmation of the presence of the parasite prior to or early in 1167 
the treatment protocol.   1168 
Relevant study designs 1169 
Relevant studies will be controlled trials that randomly allocate animals to treatment group.  1170 
1.2. Information Sources (PRISMA ITEM 7) 1171 
The searches for this review have already been designed and conducted as part of the scoping review. 1172 
This approach has been used to make maximum use of the time available for the project. The 1173 
following databases were searched: Science Citation Index (SCI), Conference Proceedings Citation 1174 
Index – Science (CPCI-S), CAB Abstracts , BIOSIS Citation Index , MEDLINE and MEDLINE In-1175 
Process, and Open Grey. These searches will not be updated as the time frame for execution of the 1176 
review is limited and the time between the scoping review and the conduct of the review is < 2 1177 
months.   1178 
The only additional resource that will be used for the systematic review will be to evaluate if relevant 1179 
references are present in the bibliography of papers that are included in the final review. The results of 1180 
this additional search will be included in the summary of search provided in the report.  1181 
1.3. Search strategy (PRISMA ITEM 8) 1182 
The search strategy is reported in Appendix D. 1183 
1.4. Study Selection (PRISMA ITEM 9) 1184 
Two reviewers will independently perform the relevance screening exercise, with disagreements on 1185 
the inclusion or exclusion of studies resolved by consensus or with the input of the review coordinator.  1186 
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 Screening for eligibility for the review 1187 
There will be two levels of screening. The rationale for two levels is that some questions will likely 1188 
require the full paper to evaluate. The following questions will be used to determine whether a study 1189 
will be included in the review: 1190 
Question 1: Does the study describe a controlled trial that assesses the treatment of Canine 1191 
leishmaniosis with one of the drugs of interest either alone or in combination with another drug of 1192 
interest?   1193 
 Yes (proceed to next question) 1194 
 No (exclude) 1195 
Question 2: Were the animals randomized to treatment group?  1196 
 Yes (proceed) 1197 
 No (exclude) 1198 
Question 3: Did the study confirm presence of parasites prior to beginning treatment or early in the 1199 
treatment protocol?  1200 
 Yes (proceed) 1201 
 No (exclude) 1202 
Question 4: Did the study test for the presence of parasites at least 12 months after the cessation of 1203 
therapy?  1204 
 Yes (proceed) 1205 
 No (exclude) 1206 
Studies remaining after Question 4 will be considered included in the report. Citations that identify 1207 
these studies will be provided in an EndNote® library. It is clear from the scoping review that the full 1208 
text is required to assess Q2 to Q4.   1209 
Screening for eligibility for meta-analysis 1210 
We do not propose to calculate a summary effect size. Instead we plan to present the findings of each 1211 
study and provide information about variation in parasitological cure.  1212 
1.5. Data collection process (PRISMA ITEM 10) 1213 
Two reviewers will extract data independently from studies deemed to be relevant to the review. Data 1214 
will be compared between the reviewers and any conflicts will be resolved through discussion. Data 1215 
extraction forms will be designed in DistillerSR®. Initial forms will be designed and piloted on several 1216 
papers and modified as required for use.  1217 
1.6. Data Items (PRISMA ITEM 11) 1218 
Information collected from each study will consist of, but is not limited to, the following: 1219 
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1.7. General study characteristics and clinical sources of heterogeneity: 1220 
 Year the study was performed (if not reported, will use the year the study was published)  1221 
 Country (must be reported or study will be excluded) 1222 
 Population of dogs: hospital, population-based, experimental  1223 
 Health status of dogs: clinically unwell, healthy, mixed, not reported (note this is very 1224 
problematic as this is an important source of heterogeneity at the individual level but the 1225 
outcome is measured at the group level- different stages of disease have the potential to 1226 
make the entire review not very useful) 1227 
 PCR assay used to confirm infection (antigen) in study dogs 1228 
1.8. Intervention characteristics (only for relevant treatment arms)  1229 
 Intervention drug protocol 1230 
 Number of dogs enrolled 1231 
 Number of dogs completing protocol 1232 
 Number of dogs completing follow-up period  1233 
 Quantity of parasites at beginning of treatment protocol if reported (average) 1234 
 Variation of mean parasite level 1235 
 Number of dogs included in above 1236 
 Units for quantity 1237 
 Duration of treatment protocol 1238 
 Duration of follow-up (from start of study) 1239 
 Duration of time not on protocol 1240 
 Number of dogs with parasitological cure (based on study assay) at the end of follow-up 1241 
Assessment of risk bias in included studies (PRISMA ITEM 12) 1242 
We will use the Cochrane risk of bias tool for intervention studies. 1243 
Summary measures (PRISMA ITEM 13) 1244 
For each relevant study arm, we will extract the prevalence of parasitological cure.  1245 
Dealing with missing data 1246 
We will not contact authors to obtain missing data. This is a potential limitation of the review. 1247 
Recently, we conducted a review and around 30% of original papers did not report measures of 1248 
variation and by contacting the authors, we were able to obtain information on numerous papers. 1249 
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However, this was a long process (months). Imputation methods for studies that do not report 1250 
measures of variation for the outcomes of interest will not be used. 1251 
Assessment of heterogeneity 1252 
We propose, if the sample size is sufficient, to conduct a meta-regression to determine what factors are 1253 
associated with the magnitude of parasitological cure. Such a model would require 10 studies per 1254 
covariate, therefore this may be a series of univariable models. We will initially try to use a log and 1255 
logit link and determine if either modelling strategy is valid.  If this is not possible we will still attempt 1256 
to present possible sources of variation using tables or subgroup figures so the panel is aware of 1257 
possible sources of heterogeneity, but formal analysis may not be possible.  1258 
Data synthesis  1259 
The approach to evidence synthesis will depend upon the frequency of the outcomes of interest within 1260 
the relevant studies. Tables that describe the outcomes used and the associations observed will be 1261 
reported. We will attempt to prepare forest plots for prevalence data.  1262 
1.9. Approach to presenting the results 1263 
1.9.1. Study selection (PRISMA ITEM 17) 1264 
We will use a flow chart as recommended by PRISMA to present the number of papers screened, the 1265 
number of relevant papers, and the number of papers included in the meta-analyses (if conducted). 1266 
1.9.2. Study characteristics (PRISMA ITEM 18) 1267 
We will provide a table that contains information about the relevant studies and other general 1268 
characteristics collected.  1269 
1.9.3. Risk of bias within studies (PRISMA ITEM 19) 1270 
We will provide a table that contains this information about relevant studies. 1271 
1.9.4. Results of individual studies (PRISMA ITEM 20) 1272 
We will provide a table that contains information about the results of relevant studies. It is possible 1273 
that there will be several tables, given the potential variety of outcomes. If suitable, we will provide a 1274 
forest plot(s) that contains individual study data in lieu of a table.  1275 
1.9.5. Synthesis of results (PRISMA ITEM 20) 1276 
Given that the aim is no longer to evaluate comparative effect, it is unlikely that a meta-analysis will 1277 
be conducted. It may be possible to provide a forest plot of prevalence estimates but this will depend 1278 
upon the data and extent of heterogeneity. If a meta-regression is conducted, we will provide the 1279 
results and interpretation of that analysis.  1280 
1.9.6. Risk of bias across studies (PRISMA ITEM 21) 1281 
If an analysis to assess small-study effects is possible, we will provide the results of that analysis. If 1282 
not, we will comment on the potential for small-study effects.  1283 
 1284 
  1285 
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C.  DIAGNOSTIC TEST EVALUATION PROTOCOL FOR THE ASSESSMENT OF DIAGNOSTIC TEST 1286 
CHARACTERISTICS OF PCR ASSAYS AND SEROLOGICAL ASSAYS (ELISA OR IFAT) FROM STUDIES 1287 
THAT USE EXPERIMENTAL MODELS OF CANINE LEISHMANIOSIS. 1288 
1. BACKGROUND AND RATIONALE   1289 
The aim of this review is to evaluate the sensitivity and specificity of assays to detect infection of 1290 
Leishmania infantum in dogs. Two types of assays are of interest, PCR assays that detect the presence 1291 
of the organism (antigen) and the serological assays, ELISA and IFAT that detect the presence of 1292 
antibodies.  1293 
Routinely data about sensitivity and specificity are obtained from observational studies that assess the 1294 
diagnostic test characteristics compared to a gold standard test. When a gold standard is not available, 1295 
two general approaches are used. One is to calculate sensitivity and specificity without a gold standard 1296 
using a host of statistical methods called latent class methods. Canine leishmaniosis has been 1297 
identified as a candidate disease which would be suitable for application of latent class methods as far 1298 
back as 1999 when Boelart et al. suggested the approach (Boelaert et al., 1999a; Boelaert et al., 1299 
1999b). More recently others have applied this approach; however as the study was not conducted in 1300 
Europe it was not considered relevant to the review (Solca Mda et al., 2014). Alternatively it is 1301 
possible to calculate relative sensitivity and specificity, picking one assay to be the referent. This 1302 
approach has the limitation that it assumes that the index assay being studied cannot be better than the 1303 
referent. As more sensitive assays are constantly being developed, this is a very major limitation. A 1304 
third possible source of data for obtaining estimates of sensitivity and specificity may be challenge 1305 
studies. These studies are unique to veterinary science, and allow deliberate exposure of a naïve 1306 
animal to an organism. This design is usually used to assess disease mechanisms, disease 1307 
pathogenesis, and intervention efficacy. It is however theoretically possible to use these to evaluate 1308 
diagnostic test characteristics. The validity of using challenge study data to obtain sensitivity and 1309 
specificity information is dependent upon the similarly between the natural mode of infection and the 1310 
experimental mode of infection. If the approach to introducing the organism into the body differs in a 1311 
manner that the host’s body reacts differently during induced infection when compared to natural 1312 
infection, then the data from the challenge study will not be appropriate. The impact of mode of 1313 
infection likely affects assays that detect antigen and antibody differently. The assessment of validity 1314 
of the inducted model requires content experts.  1315 
Most challenge studies do not report sensitivity and specificity data and therefore the ability to obtain 1316 
such data from a study relies upon the reporting approach used by the authors. Reviewers need to 1317 
extract the data and calculate the sensitivity and specificity directly. This data is generally reported as 1318 
apparent prevalence. For example, a study might infect 10 animals and report positive PCR results 1319 
from conjunctival swabs from 4 of 10 animals 3 months post-infection.  If we assume that the infected 1320 
animal is the gold standard, then the sensitivity of the assay at 3 months post-infection might be 1321 
reported as 40% (95% confidence interval 28% - 72%). If the study does not include a negative control 1322 
dog, the specificity cannot be calculated. Also with respect to specificity, as dogs in experimental 1323 
studies are rarely exposed to possible sources of false positives (i.e., other organism that may have 1324 
similar antigens), estimates of specificity from such studies will likely suffer from spectrum bias and 1325 
always be overestimated.  1326 
In this document we provide a proposed protocol for extracting, calculating, and summarizing data 1327 
from challenge studies that could be used to inform the EFSA working group about sensitivity and 1328 
specificity.  1329 
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2. Objectives   1330 
The objective of this review is to summarize relative diagnostic test sensitivity and specificity 1331 
estimates reported in experimental studies of dogs infected with Leishmania infantum associated with 1332 
infection in Europe i.e. excluding studies evaluating L. Mexicana or L. brasiliensi infection.   1333 
3. METHODS   1334 
3.1. Criteria for considering studies for this review   1335 
3.1.1. Types of studies 1336 
Studies that enroll dogs that are naïve for Leishmania infantum infection and deliberately infect them 1337 
with Leishmania infantum are eligible for inclusion. The studies must also follow the dog over time to 1338 
detect changes in Leishmania infantum infection status using any PCR assay as a measure of antigen 1339 
presence and ELISA or IFAT as measures of serological exposure to Leishmania infantum.   1340 
3.1.2. Participants  1341 
The target population of interest is naïve dogs at risk of Leishmania infantum infection in Europe 1342 
introduced into or living in endemic regions.  1343 
3.1.3. Index and comparator tests  1344 
The aim is to extract sensitivity and specificity data from these studies. The authors may test the 1345 
animals with a PCR or serology test of choice during the study and determine the apparent prevalence 1346 
of infection. Then the authors may compare the results of the PCR of choice to other PCR assays, the 1347 
same PCR assay on a different tissue or the serological assays ELISA or IFAT. Therefore, the gold 1348 
standard will be the authors’ “preferred” PCR and will change between studies. The comparator test 1349 
will be that reported by the authors, provided it is either a PCR test/tissue or ELISA or IFAT. 1350 
Apparent prevalence data will not be extracted. 1351 
3.1.4. Target conditions  1352 
The target condition of interest is infection with leishmaniosis caused by infection with Leishmania 1353 
infantum based on the authors’ preferred PCR assay and test sample.   1354 
3.1.5. Search methods for identification of studies   1355 
3.1.5.1. Electronic searches  1356 
The searches for this review are below. 1357 
# 3 #2 AND #1 1358 
# 2 canine" OR "canines" OR "dog" OR "dogs" OR "lupus familiaris" OR "l familiaris" OR 1359 
canidae* OR "canid" OR "canids") 1360 
# 1 TS=("leishmaniosis" OR "leishmaniasis" OR "leishmania" OR "l infantum") 1361 
This search differs slightly from the search designed for observational studies; however, as the review 1362 
is now using induced disease models there is no valid reason for such a limitation because if a 1363 
challenge study was conducted in either North or South America using the organism of interest it 1364 
would still be relevant to the review.  The sources that should be searched are Science Citation Index 1365 
(SCI), Conference Proceedings Citation Index – Science (CPCI-S), CAB Abstracts, BIOSIS Citation 1366 
Index. MEDLINE and MEDLINE In-Process, and Open Grey.  1367 
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3.1.6.  Searching other resources 1368 
We will evaluate if relevant references are present in the bibliographies of papers that are included in 1369 
the final review. Also reviews identified during the screening process that are likely to contain 1370 
references to induced disease models of Leishmania should be flagged, obtained, and evaluated i.e., 1371 
pathogenesis reviews and immunology reviews.   1372 
3.1.7. Selection of studies   1373 
Level 1 Screening 1374 
The review will require two levels of screening, one based on only the abstract and title of the citation.  1375 
For the 2
nd
 level of screening the full texts will need to be obtained as the required information may 1376 
not be included in the abstract. Two independent reviewers should review each citation. Citations with 1377 
yes responses from both reviewers should be passed to the second level of screening and text. 1378 
Citations with conflicts should be resolved by discussion between the 2 reviewers. Citations with two 1379 
“no” responses are excluded without further evaluation.  Prior to screening at both levels, the 1380 
screening questions will be tested on a test set of at least 100 abstracts and modified as necessary. 1381 
When agreement between the two independent reviewers is high (kappa > 90%) screening of all 1382 
abstracts will take place.  1383 
Question 1: Does the title or abstract describe a primary study of dogs that are likely be an induced 1384 
model of canine leishmaniosis? 1385 
Yes- proceed to level 2 1386 
 No (exclude) 1387 
 1388 
Level 2 screening  1389 
1) Does the study include canine leishmaniosis relevant to European dog populations?  1390 
Yes- next question 1391 
 No (exclude) 1392 
2)  Does the study include data which may be used to calculate the diagnostic test characteristics 1393 
of the following assays of interest for canine leishmaniosis: PCR, IFAT, or ELISA? Include 1394 
studies with data in figures, tables, or text. Note the data may report apparent prevalence or 1395 
true prevalence and is unlikely to be reported as sensitivity and specificity.  1396 
Yes- proceed to data extraction 1397 
 No (exclude) 1398 
3.1.8. Data collection  1399 
After identifying the studies eligible for the review, extraction of study characteristics and results will 1400 
occur and the risk of bias in each study will be assessed. Data collection forms will be developed 1401 
based on the questions below. The forms will be tested on a subset of studies to ensure high agreement 1402 
between reviewers. Data extraction will be performed by two reviewers and conflicts resolved by 1403 
discussion.  1404 
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Note that care will need to be taken in designing the forms, as the review is not extracting a single 1405 
pairwise comparison. For example, a single study may report prevalence of PCR-positive bone 1406 
marrow at 2, 5, and 12 months post-infection, prevalence of PCR-positive lymph node aspirates at 2, 1407 
5, and 12 months post-infection, and prevalence of ELISA-positive sera at 2, 5, 7 and 12 months post-1408 
infection.  1409 
3.1.8.1. Form 1: Characteristics of the study population to be collected: 1410 
1) Country- list of EU member countries and a text box for others options 1411 
2) Year that study was conducted (XXXX). If the study doesn’t report the year, this will be not 1412 
reported rather than using the year of publication.  1413 
3) Origin of dog population –local kennel dogs, laboratory breed dogs, imported from another 1414 
region, 1415 
4) Breed of dog 1416 
5) Central tendency for age of dogs infected (median, mean, not reported) 1417 
6) Units for age of dogs (days, weeks, months, years) 1418 
7) Number that corresponds to 21, (i.e., if the authors reported the median age was 9 weeks, then 1419 
report the following  - 21 = median, 22 = weeks, 23= 9 1420 
8) Measure of precision used for age of dogs (confidence interval, range, SE, SD) 1421 
9) Number that corresponds to 24 1422 
10) Central tendency for weight of dogs infected (median, mean, not reported) 1423 
11) Number that corresponds to 26 (i.e., if the authors reported the mean weight was 15 lbs, then 1424 
report the following  - 26=mean, and 27-33 (convert all weights to kg) 1425 
12) Measure of precision used for weight of dogs (confidence interval, range, SE, SD) 1426 
13) Number that corresponds to 28 (remember to convert correctly if changing SEM from lbs to 1427 
kgs)  1428 
3.1.8.2. Form 2: Characteristics of the induced disease model  1429 
(Repeat this form for each arm of the trial). If the study has two doses and one negative control group, 1430 
this means the study has three arms and therefore this form should be completed three times for each 1431 
review)  1432 
1) Study arm designation (Free text- must match between reviewers) 1433 
2) Organism used to infect dogs (text) 1434 
3) Lifecycle stage used to infect dogs 1435 
4) Route used to infect dogs (intravenous, intraperitoneal, etc.) 1436 
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5) Dose used to infect dogs (use international standard units and convert if necessary) 1437 
6) Additional treatments (immune suppression etc.- provide text) 1438 
7) For negative groups describe if any additional factors included to adjust specificity i.e., 1439 
exposure to other organisms etc. 1440 
3.1.8.3. Form 3: Outcome data form – multiple repeats 1441 
Repeat for each assay at each time point for each study arm used i.e., each reviewer should 1442 
complete this form 4 times if the study assessed BM PCR, LN PCR, ELISA and IFAT at 2 1443 
months, and 8 times if the study assessed BM PCR, LN PCR, ELISA and IFAT at 2 and 4 months 1444 
and 12 times if the study assessed BM PCR, LN PCR, ELISA and IFAT at 2, 4 and 12 months. 1445 
Two reviewers should complete each form and resolve conflicts.   1446 
1) Study arm  1447 
2) Method used to assess prevalence  (pick one: PCR, ELISA, IFAT, None) 1448 
3) Authors’ description of the approach to the assay (text-based)  1449 
4) What is the cut-off for a positive ELISA assay used to assess positive diagnosis? Text 1450 
(indicate NR if not reported or leave blank if not applicable) 1451 
5) What is the cut-off for a positive PCR assay used to assess positive diagnosis? Text (indicate 1452 
NR if not reported or leave blank if not applicable) 1453 
6) Tissues used for this assay at this time point (skin, bone marrow, lymph node aspirate, 1454 
conjunctiva fluids, serum, plasma, other, not reported) 1455 
7) Time post-infection of testing (enter data as months)   1456 
8) Number of dogs infected 1457 
9) Number of dogs positive (if necessary, extract from figures- if reported as percentage – 1458 
calculate the number positive to obtain the percentage) 1459 
10) Reported sensitivity (express as a proportion, leave blank if not reported, or a control arm)  1460 
11) Measure of precision of sensitivity  (express as SE- back convert CI by dividing by 4)  1461 
12) Reported specificity (express as a proportion- if a control arm only - leave these question 1462 
blank if positive arm). Specificity will be 1 minus proportion of positive dogs.  1463 
13) Measure of precision of specificity  (express as SE- back convert CI by dividing by 4)  1464 
14) Time post-introduction to infection exposure (rounded to nearest month, if 2 weeks use 0.5)  1465 
3.1.8.4. Assessment of methodological quality  1466 
Assessment of methodological quality will be based upon the QUADAS tool domains for diagnostic 1467 
test comparisons (Whiting et al., 2003; Whiting et al., 2006; Whiting et al., 2011). Consistent with the 1468 
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recommendations from the Cochrane Working Group on Diagnostic Test Evaluations Systematic 1469 
Reviews we will assess the following questions that relate to quality of study execution. (even when 1470 
some are eligibility criteria) (Reitsma et al., 2009). Assessment of methodological bias will be 1471 
performed by two reviewers independently and conflicts resolved by discussion. This form should be 1472 
tested prior to extracting data to ensure that all reviewers understand the bias domains. These 1473 
questions should be completed for each assay, because the potential for bias may differ among PCR, 1474 
ELISA, and IFAT. In particular, the approach to inducing disease may affect the “validity” of the 1475 
serology models more than the PCR methods. All questions should be answered as high, low, or 1476 
unclear risk of bias. More information on how to assess the risk of bias can be found in the Cochrane 1477 
Handbook; however, that source does not use the same domains of bias as reported here.   1478 
1. Was the spectrum of infected dogs representative of the dogs that will receive the test in practice 1479 
(representative spectrum)? This question asks if the laboratory dogs are biologically similar to the 1480 
dogs that would be tested. This refers just to the host (not the model). For example, if the study 1481 
includes only puppies, and the assays will eventually be used in adults and the expected responses are 1482 
different in pups compared to adults, then the answer would be high risk of bias. Provide a 1-2 1483 
sentence rationale for any high or unclear answer.  1484 
1b. Was the challenge model likely to induce an assay response that is representative of the real 1485 
infection? Factors that may be important are the route or dose. This question asks if the disease model 1486 
is biologically similar to natural infection. Provide a 1-2 sentence rationale for any high or unclear 1487 
answer. 1488 
2.  Is the reference standard likely to classify the target condition correctly (acceptable reference 1489 
standard)? In this situation the reference standard is challenge. The answer here should always be low 1490 
risk of bias, unless there is a concern that the animals are not actually infected i.e., the model failed to 1491 
infect animals. This is different from Question 1b, which assumes the model is effective at infecting 1492 
animals but the approach may mean the animals’ response is dissimilar to natural infection.  1493 
3.  Is the time period between reference standard and index test short enough to be reasonably sure that 1494 
the target condition did not change between the two tests (acceptable delay between tests)? For 1495 
challenge studies this question asks if the time that has passed between infection and testing is valid. 1496 
This refers mainly to PCR assays, and would usually be low risk of bias, provided the experts believe 1497 
the animals are still infected. If some of animals that were deliberately infected are thought for some 1498 
reason to have been cured, then the risk of bias would be high if the index test is conducted many 1499 
months after infection.  1500 
4.  Did the whole sample or a random selection of the sample receive verification using the intended 1501 
reference standard (partial verification avoided)? If the study does not test all the dogs (except dead 1502 
dogs) that were originally infected, assume a high risk of bias.  1503 
5.  Did dogs receive the same reference standard irrespective of the index test result (differential 1504 
verification avoided)? Not applicable for challenge studies  1505 
6.  Was the reference standard independent of the index test (i.e. the index test did not form part of the 1506 
reference standard) (incorporation avoided)? Not applicable for challenge studies 1507 
7.  Were the reference standard results interpreted without knowledge of the results of the index test 1508 
(index test results blinded)?  If the authors do not report blinding of the animals’ status or the study 1509 
only contains infected animals then assess a high risk of bias.  1510 
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8.  Were the index test results interpreted without knowledge of the results of the reference standard? 1511 
If the authors do not report blinding of the outcome, we will assess a high risk of bias. 1512 
9.  Were the same clinical data available when test results were interpreted as would be available when 1513 
the test is used in practice? If the authors describe having access to clinical data i.e., testing sick dogs, 1514 
then we will assess a high risk of bias, as we assume that candidate dogs will not have clinical signs 1515 
when tested. 1516 
10.  Were uninterpretable/intermediate test results reported? If the authors report discarding 1517 
intermediate test results we will assess a high risk of bias; if the authors do not discuss intermediate 1518 
results, we will report an unclear risk of bias. 1519 
11.  Were withdrawals from the study explained? If the authors describe > 10% loss to follow-up we 1520 
will assign a high risk of bias. If the authors do not report the number of animals that were used in 1521 
sensitivity and specificity assessment we will assign an unclear risk of bias, and if all animals are 1522 
present and accounted for we will assess low risk of bias. Note that death is not a reason for loss-to-1523 
follow up, rather it is a valid withdrawal.  1524 
After each reviewer has assessed the risk of bias, the reviewers will resolve conflicts and rationales 1525 
and provide a single summary rationale for each question for each assay for each study.  1526 
3.1.8.5. Statistical analysis and data synthesis 1527 
As the analysis will to some extent depend upon the type and quantity of data that are located through 1528 
the literature search, it is not possible to fully specify the analysis at the protocol stage. In general 1529 
terms we propose to use a hierarchical random-effects model or a generalized linear model as 1530 
recommended for binary outcome data to model each pairwise comparison (Macaskill et al., 2010). If 1531 
conducted, preliminary analysis and forest plots can be constructed in RevMan. If conducted, 1532 
complicated analyses will be conducted either in SAS using Proc GLIMMIX or R (using one of 1533 
several packages).  1534 
3.1.8.6. Investigations of heterogeneity  1535 
It will be very difficult to explore sources of heterogeneity across all studies using standard approaches 1536 
because there is no pairwise comparison (Macaskill et al., 2010).  However, the major sources of 1537 
heterogeneity should only be explored nested within the same assay, for example, within studies that 1538 
assess PCR on bone marrow. The characteristics of the host (age, weight) and the model (dose, route) 1539 
are likely sources of heterogeneity and should be explored and the results reported for each assay.  1540 
3.1.8.7. Reporting 1541 
Tables should be reported that contain 1) the general characteristics, 2) the induced model 1542 
characteristics, 3) the assays’ characteristics, and 4) results for each study. For the results, raw data and 1543 
the percentage-based data with confidence intervals should be reported. Risk of bias should be 1544 
reported for each study. Summaries presented can be pairwise if meta-analyses is conducted for each 1545 
assay compared to induced infection.  1546 
 1547 
 1548 
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D.  SEARCH STRATEGIES 1549 
D1. CAB Abstracts (Web of Science – Thomson Reuters) 1910-current.  Searched 06/05/14 1550 
# 7 2,815 #3 NOT #6 1551 
# 6 2,213,258 #4 NOT #5 1552 
# 5 2,592,003 AD=(Albania* OR Andorra* OR Armenia* OR Austria* OR Azerbaija* OR 1553 
Belarus* OR Belgium* OR Bosnia* OR Bulgaria* OR Croatian* OR Cyprus* OR Cypriot* OR 1554 
Czech* OR Denmark* OR “Danish” OR Estonia* OR Finland* OR “Finns” OR “Finnish” OR 1555 
Macedonia* OR France* OR “French” OR Georgia* OR German* OR Greece* OR Greek* OR 1556 
Hungary* OR Hungarian* OR Iceland* OR Ireland* OR “Irish” OR Italy* OR Italian* OR Israel* OR 1557 
Kazakhstan* OR Kyrgyzstan* OR Latvia* OR Liechtenstein* OR Lithuania* OR Luxemburg* OR 1558 
Luxembourger* OR Malta* OR Moldavia* OR Montenegro* OR Netherlands OR Holland* OR 1559 
“Dutch” OR Norway* OR Norwegian* OR Poland* OR “Polish” OR Portugal* OR “Portuguese” OR 1560 
Romania* OR Russia* OR “San Marin*” OR Serbia* OR Slovakia* OR Slovenia* OR Spain* OR 1561 
Sweden* OR “Swedish” OR “Swiss” OR Switzerland* OR Tajikistan* OR Turkey* OR “Turkish” 1562 
OR Turkmenistan* OR Ukrain* OR “United Kingdom*” OR “UK” OR Britain* OR “British” OR 1563 
England* OR “English” OR Wales* OR “Welsh” OR Scotland* OR “Scottish” OR Uzbekistan* OR 1564 
“USSR” OR “Soviet”) 1565 
# 4 2,289,308 AD=("united states" OR america* OR "USA" OR "US" OR "canada" OR 1566 
canadian* OR "mexico" OR mexican* OR brazil* OR colombia* OR argentin* OR peru OR 1567 
"peruvian" OR venezuela* OR chile* OR ecuador* OR bolivia* OR paragua* OR urugua* OR 1568 
guyana* OR suriname* OR guiana* OR "cuba" OR "cuban" OR guatemala* OR "haiti" OR "haitian" 1569 
OR bolivia* OR dominican* OR hondura* OR "el salvador*" OR nicaragua* OR "costa rica*" OR 1570 
"puerto ric*" OR panama* OR ethiopia* OR sudan* or kenya* OR africa* OR australia*) 1571 
# 3 3,959 #2 AND #1 1572 
# 2 203,952 TS= ("canine" OR "canines" OR "dog" OR "dogs" OR "lupus familiaris" OR "l 1573 
familiaris" OR canidae* OR "canid" OR "canids") 1574 
# 1 27,913 TS= ("leishmaniosis" OR "leishmaniasis" OR "leishmania" OR "l infantum") 1575 
D2. Social Science Citation Index – Expanded (Web of Science, Thomson Reuters) 1900-2014-05-1576 
02.  Searched 06/05/14 1577 
# 7 1,594 #3 NOT #6 1578 
# 6 10,670,857 #4 NOT #5 1579 
# 5 14,605,415 AD=(Albania* OR Andorra* OR Armenia* OR Austria* OR Azerbaija* OR 1580 
Belarus* OR Belgium* OR Bosnia* OR Bulgaria* OR Croatian* OR Cyprus* OR Cypriot* OR 1581 
Czech* OR Denmark* OR “Danish” OR Estonia* OR Finland* OR “Finns” OR “Finnish” OR 1582 
Macedonia* OR France* OR “French” OR Georgia* OR German* OR Greece* OR Greek* OR 1583 
Hungary* OR Hungarian* OR Iceland* OR Ireland* OR “Irish” OR Italy* OR Italian* OR Israel* OR 1584 
Kazakhstan* OR Kyrgyzstan* OR Latvia* OR Liechtenstein* OR Lithuania* OR Luxemburg* OR 1585 
Luxembourger* OR Malta* OR Moldavia* OR Montenegro* OR Netherlands OR Holland* OR 1586 
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“Dutch” OR Norway* OR Norwegian* OR Poland* OR “Polish” OR Portugal* OR “Portuguese” OR 1587 
Romania* OR Russia* OR “San Marin*” OR Serbia* OR Slovakia* OR Slovenia* OR Spain* OR 1588 
Sweden* OR “Swedish” OR “Swiss” OR Switzerland* OR Tajikistan* OR Turkey* OR “Turkish” 1589 
OR Turkmenistan* OR Ukrain* OR “United Kingdom*” OR “UK” OR Britain* OR “British” OR 1590 
England* OR “English” OR Wales* OR “Welsh” OR Scotland* OR “Scottish” OR Uzbekistan* OR 1591 
“USSR” OR “Soviet”) 1592 
# 4 12,565,534 AD=("united states" OR america* OR "USA" OR "US" OR "canada" OR 1593 
canadian* OR "mexico" OR mexican* OR brazil* OR colombia* OR argentin* OR peru OR 1594 
"peruvian" OR venezuela* OR chile* OR ecuador* OR bolivia* OR paragua* OR urugua* OR 1595 
guyana* OR suriname* OR guiana* OR "cuba" OR "cuban" OR guatemala* OR "haiti" OR "haitian" 1596 
OR bolivia* OR dominican* OR hondura* OR "el salvador*" OR nicaragua* OR "costa rica*" OR 1597 
"puerto ric*" OR panama* OR ethiopia* OR sudan* or kenya* OR africa* OR australia*)3  1598 
# 3 2,382 #2 AND #1 1599 
# 2 267,783 TS= ("canine" OR "canines" OR "dog" OR "dogs" OR "lupus familiaris" OR "l 1600 
familiaris" OR canidae* OR "canid" OR "canids") 1601 
# 1 29,195 TS= ("leishmaniosis" OR "leishmaniasis" OR "leishmania" OR "l infantum") 1602 
D3. Conference Proceedings Citation Index – Science (Web of Science, Thomson Reuters) 1900-1603 
2014-05-02.  Searched 06/05/14 1604 
# 3 101 #2 AND #1 1605 
# 2 15,822 TS= ("canine" OR "canines" OR "dog" OR "dogs" OR "lupus familiaris" OR "l 1606 
familiaris" OR canidae* OR "canid" OR "canids") 1607 
# 1 1,498 TS= ("leishmaniosis" OR "leishmaniasis" OR "leishmania" OR "l infantum") 1608 
D4. Biosis Citation Index (Web of Science – Thomson Reuters) 1969-2014/05/02.  Searched 1609 
06/05/14 1610 
# 7 1,352 #3 NOT #6 1611 
# 6 8,250,669 #4 NOT #5 1612 
# 5 6,775,652 AD=(Albania* OR Andorra* OR Armenia* OR Austria* OR Azerbaija* OR 1613 
Belarus* OR Belgium* OR Bosnia* OR Bulgaria* OR Croatian* OR Cyprus* OR Cypriot* OR 1614 
Czech* OR Denmark* OR “Danish” OR Estonia* OR Finland* OR “Finns” OR “Finnish” OR 1615 
Macedonia* OR France* OR “French” OR Georgia* OR German* OR Greece* OR Greek* OR 1616 
Hungary* OR Hungarian* OR Iceland* OR Ireland* OR “Irish” OR Italy* OR Italian* OR Israel* OR 1617 
Kazakhstan* OR Kyrgyzstan* OR Latvia* OR Liechtenstein* OR Lithuania* OR Luxemburg* OR 1618 
Luxembourger* OR Malta* OR Moldavia* OR Montenegro* OR Netherlands OR Holland* OR 1619 
“Dutch” OR Norway* OR Norwegian* OR Poland* OR “Polish” OR Portugal* OR “Portuguese” OR 1620 
Romania* OR Russia* OR “San Marin*” OR Serbia* OR Slovakia* OR Slovenia* OR Spain* OR 1621 
Sweden* OR “Swedish” OR “Swiss” OR Switzerland* OR Tajikistan* OR Turkey* OR “Turkish” 1622 
OR Turkmenistan* OR Ukrain* OR “United Kingdom*” OR “UK” OR Britain* OR “British” OR 1623 
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England* OR “English” OR Wales* OR “Welsh” OR Scotland* OR “Scottish” OR Uzbekistan* OR 1624 
“USSR” OR “Soviet”) 1625 
# 4 8,409,714 AD=("united states" OR america* OR "USA" OR "US" OR "canada" OR 1626 
canadian* OR "mexico" OR mexican* OR brazil* OR colombia* OR argentin* OR peru OR 1627 
"peruvian" OR venezuela* OR chile* OR ecuador* OR bolivia* OR paragua* OR urugua* OR 1628 
guyana* OR suriname* OR guiana* OR "cuba" OR "cuban" OR guatemala* OR "haiti" OR "haitian" 1629 
OR bolivia* OR dominican* OR hondura* OR "el salvador*" OR nicaragua* OR "costa rica*" OR 1630 
"puerto ric*" OR panama* OR ethiopia* OR sudan* or kenya* OR africa* OR australia*) 1631 
# 3 2,202 #2 AND #1 1632 
# 2 331,977 TS= ("canine" OR "canines" OR "dog" OR "dogs" OR "lupus familiaris" OR "l 1633 
familiaris" OR canidae* OR "canid" OR "canids") 1634 
# 1 26,006 TS= ("leishmaniosis" OR "leishmaniasis" OR "leishmania" OR "l infantum") 1635 
D5. Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 1636 
MEDLINE(R) <1946 to Present> Searched 07/05/14 1637 
1     (leishmaniosis or leishmaniasis or leishmania or l infantum).ti,ab. (24460) 1638 
2     exp Leishmaniasis/ (17146) 1639 
3     exp Leishmania/ (15162) 1640 
4     1 or 2 or 3 (27328) 1641 
5     (canine or canines or dog or dogs or lupus familiaris or l familiaris or canidae* or canid or 1642 
canids).ti,ab. (214185) 1643 
6     Dogs/ (283536) 1644 
7     Dog Diseases/ (44732) 1645 
8     5 or 6 or 7 (323510) 1646 
9     4 and 8 (2374) 1647 
10     exp Europe/ (1093594) 1648 
11     exp africa/ or exp americas/ or exp australia/ (1629998) 1649 
12     (united states or america* or USA or US or canada or canadian* or mexico or mexican* or 1650 
brazil* or colombia* or argentin* or peru or peruvian or venezuela* or chile* or ecuador* or bolivia* 1651 
or paragua* or urugua* or guyana* or suriname* or guiana* or cuba or cuban or guatemala* or haiti or 1652 
haitian or bolivia* or dominican* or hondura* or el salvador* or nicaragua* or costa rica* or puerto 1653 
ric* or panama* or ethiopia* or sudan* or kenya* or africa* or australia*).in. (4474430) 1654 
13     (Albania* or Andorra* or Armenia* or Austria* or Azerbaija* or Belarus* or Belgium* or 1655 
Bosnia* or Bulgaria* or Croatian* or Cyprus* or Cypriot* or Czech* or Denmark* or Danish or 1656 
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Estonia* or Finland* or Finns or Finnish or Macedonia* or France* or French or Georgia* or 1657 
German* or Greece* or Greek* or Hungary* or Hungarian* or Iceland* or Ireland* or Irish or Italy* 1658 
or Italian* or Israel* or Kazakhstan* or Kyrgyzstan* or Latvia* or Liechtenstein* or Lithuania* or 1659 
Luxemburg* or Luxembourger* or Malta* or Moldavia* or Montenegro* or Netherlands or Holland* 1660 
or Dutch or Norway* or Norwegian* or Poland* or Polish or Portugal* or Portuguese or Romania* or 1661 
Russia* or San Marin* or Serbia* or Slovakia* or Slovenia* or Spain* or Sweden* or Swedish or 1662 
Swiss or Switzerland* or Tajikistan* or Turkey* or Turkish or Turkmenistan* or Ukrain* or United 1663 
Kingdom* or UK or Britain* or British or England* or English or Wales* or Welsh or Scotland* or 1664 
Scottish or Uzbekistan* or USSR or Soviet).in. (4532270) 1665 
14     (11 or 12) not (10 or 13) (5175568) 1666 
15     9 not 14 (1525) 1667 
D6.  Open Grey http://www.opengrey.eu/ Searched 07/05/14 1668 
(canine OR canines OR dog OR dogs OR lupus familiaris OR l familiaris OR canidae* OR canid OR 1669 
canids) AND (leishmaniosis OR leishmaniasis OR leishmania OR "l infantum") 1670 
23 results – 18 added to EndNote®, 5 records of epidemiological studies taking place in non-European 1671 
countries so not downloaded.   1672 
 1673 
  1674 
 Scoping review and protocols for 
Canine Leishmania  
 
Supporting publications 2015:EN-761 88 
   
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively 
by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender 
procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be 
considered as an output adopted by the Authority. The European food Safety Authority reserves its rights, view and position as regards the 
issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors. 
 
 1675 
E.  RISK OF BIAS QUESTIONS FOR OBJECTIVE 1 1676 
Question 
1) Spectrum of naïve dogs representative of the dogs who will receive the test in practice?  
  Yes, they were representative 
  No, they were not representative 
  Not discernible 
1a) What was the risk of bias due to the representative spectrum of the naive dogs? 
  Low 
  High 
  Unclear 
Notes: Aimed at assessing representative spectrum. The answer to this is likely to be an unclear risk of 
bias as it is unclear to the review team that the candidates for testing are likely to be naïve dogs with 
short-term exposure to infection pressure. The review team suspects that some candidate dogs will also 
include dogs from endemic regions which may have different exposure to other organisms and long-
term exposure. 
 
2) Is the reference standard likely to classify the target condition correctly?  
  Yes, the referent was a kDNA PCR used on bone marrow. 
  No, the referent was not a kDNA PCR used on bone marrow. 
  Not discernible (a PCR was used on bone marrow but it is unclear whether it was a kDNA PCR) 
2a) What was the risk of bias due to the acceptability of the reference standard? 
  Low 
  High 
  Unclear 
Notes: Aimed at assessing an acceptable reference standard. We will answer "Yes" (low risk of bias) 
to this question if the reference assay is a bone marrow-based kDNA PCR assay; otherwise, we will 
assume the referent could not classify Leishmania status correctly and conclude a high risk of bias. 
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3) Is the time period between reference standard and index test short enough to be reasonably sure that 
the target condition did not change between the two tests? (acceptable delay between tests) 
  Yes, the tests were run concurrently. 
  No, the tests were not run concurrently or the timing of the tests was not discernible. 
3a) What was the risk of bias due to the acceptability of delay between tests? 
  Low 
  High 
  Unclear 
Notes: Aimed at assessing acceptable delay between tests. If the tests were not conducted 
concurrently, we answered "No" to this question (high risk of bias). 
 
4) Did the whole sample or a random selection of the sample receive verification using the intended 
reference standard?  
  Yes, all originally naïve dogs tested with referent 
  No, not all originally naïve dogs tested with referent 
What was the risk of bias due to avoidance of partial verification? 
  Low 
  High 
  Unclear 
Notes: Aimed to assess partial verification. If the study does not test all of the dogs (except dead dogs) 
that were originally identified as naïve, we will answer "No" and assume a high risk of bias. 
 
5) Did dogs receive the same reference standard irrespective of the index test result?  
  Yes, all dogs were tested with the same referent test irrespective of the index test result. 
  No, some dogs were not retested due to results of a single previous test (or this was not discernible). 
5a) What was the risk of bias due to avoidance of differential verification? 
  Low 
  High 
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  Unclear 
Notes: Aimed at assessing differential verification bias. If the study uses a different reference or index 
test to test a subset of dogs, we will answer "No" and assume a high risk of bias--e.g., if only animals 
that tested positive (or negative) based on one assay were retested later in the follow-up period. 
 
6) Was the reference standard independent of the index test (i.e. the index test did not form part of the 
reference standard)?  
  Yes, the referent test was independent of the index test. 
  No, the referent test was not independent of the index test (or this was not discernible). 
6a) What was the risk of bias due to avoidance of incorporation? 
  Low 
  High 
  Unclear 
Notes: Aimed at assessing incorporation avoided. If the authors used the index test as part of the 
reference test, we will assign a high risk of bias. 
 
7) Were the reference standard results interpreted without knowledge of the results of the index test? 
(index test results blinded) 
  Yes, the outcome assessors were blinded. 
  No, the outcome assessors were not blinded (or this was not reported). 
7a) What was the risk of bias due to lack of blinding of index test results during reference standard 
result interpretation? 
  Low 
  High 
  Unclear 
 
Notes: Aimed at assessing misclassification bias due to index test results blinded: If the authors do not 
report blinding of the outcome, we will assess a high risk of bias 
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8) Were the index test results interpreted without knowledge of the results of the reference standard? 
  Yes, outcome assessors were blinded. 
  No, outcome assessors were not blinded (or this was not reported). 
8a) What was the risk of bias due to lack of blinding of the referent test results during interpretation of 
index test results? 
  Low 
  High 
  Unclear 
Notes: Aimed at assessing misclassification bias due to reference test results unblinded. If the authors 
do not report blinding of the outcome we will assess a high risk of bias. 
  
 
9) Were uninterpretable or intermediate test results reported? 
  Yes, intermediate test results were reported. 
  No, intermediate test results were discarded and not included in measures of sensitivity and 
specificity. 
  The authors did not discuss intermediate test results. 
9a) What was the risk of bias due to intermediate test results? 
  Low 
  High 
  Unclear 
Notes: If the authors report discarded intermediate test results, we will assess a high risk of bias; if the 
authors do not discuss intermediate results, we will report an unclear risk of bias. 
 
10) Were withdrawals from the study explained? 
  Yes, data from all dogs were presented and losses accounted for. 
  No, there was >10% loss to follow-up. 
  The authors did not report the number of animals used to calculate sensitivity and/or specificity. 
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10a) What was the risk of bias due to loss to follow-up? 
  Low 
  High 
  Unclear 
Notes: If the authors describe >10% loss to follow-up, we will assign a high risk of bias. If the authors 
do not report the number of animals that were used in the calculation of sensitivity and specificity, we 
will assign unclear risk of bias. If data from all animals are reported, we will assess low risk of bias. 
Note that death is not considered loss to follow-up, but a valid withdrawal. 
 1677 
 1678 
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F.  RISK OF BIAS QUESTIONS FOR OBJECTIVE 2 1680 
 1681 
Bias domain: Selection bias 
Was allocation to treatment group randomized? 
  Random allocation 
  Non-random allocation 
  Not reported/Not discernible 
What was the risk of bias due to allocation method? 
  Low 
  High 
  Unclear 
Does the study describe the method used to conceal allocation? 
  Yes 
  No 
What was the risk of bias due to allocation concealment? 
  Low 
  High 
  Unclear 
Bias domain: Performance bias 
Were measures to blind owners/personnel described? 
  Yes 
  No 
What was the ROB due to knowledge of the allocated interventions by owners/handlers/personnel during 
the study? 
  Low 
  High 
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  Unclear 
Bias domain: Detection bias 
Do the authors describe measures to blind outcome assessors? 
  Yes 
  No 
What was the ROB due to knowledge of the allocated interventions by outcome assessors? 
  Low 
   
  High 
 
  Unclear 
 
Rationale for ROB due to blinding of outcome assessors 
Bias domain: Attrition bias 
Were there incomplete outcome data in the study? 
  No loss to follow-up 
  Loss to follow-up but explained 
  Loss to follow-up not explained 
What was the ROB due to amount, nature, or handling of incomplete outcome data? 
  Low 
 
  High 
 
  Unclear 
 
Rationale for ROB due to incomplete outcome data 
Bias domain: Reporting bias 
Was there selective reporting of outcomes? 
  Yes 
  No 
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What was the risk of bias due to selective outcome reporting? 
  Low 
  High 
  Unclear 
Rationale for ROB due to selective reporting of outcomes 
Other bias 
Was the sensitivity of the assay(s) used at follow-up reported? 
  Yes 
  No 
What was the risk of bias due to follow-up diagnostic test sensitivity? 
  Low 
  High 
  Unclear 
Rationale for ROB due to follow-up test sensitivity 
Other potential sources of bias identified: State any important concerns about bias not covered in the other 
domains in the tool. 
What was the risk of bias due to other potential sources of bias not identified in the preceding questions? 
  Low 
  High 
  Unclear 
Rationale for ROB due to other sources of bias 
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